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ABSTRACT 
 
 The first part of my dissertation focuses on the expression and function of PPARs 
in human melanoma.  I found that the A375 cells were significantly growth inhibited 
in response to PGJ2 and troglitazone treatment.  HEMn-LP showed significant 
growth inhibition in response to troglitazone.   I found that PPARγ and PPARδ 
mRNA is present in both the SK-Mel 28 and A375 cells.  The relative level of PPARα 
mRNA expression is highest in SK-Mel 28 cells, ~3 fold higher relative to both the 
normal human melanocytes and A375 cells.  PPARγ protein was ~50% higher in 
both SK-Mel 28 and A375 cells relative to the HEMn-LP.  PPARα protein levels were 
highest in the A375 cells.  Consistent 80% knockdown of PPARα was achieved 
through siRNA treatment; however, there was no change in cellular morphology.   
There was also no decrease in expression of a direct PPARα target, MCAD.  
Therefore, a reasonable conclusion is that the increased expression of PPARα in 
SK-Mel28 cells is not contributing to its in vitro transformed phenotype. 
Hypoxia inducible factor 1α, HIF-1α, is a transcription factor that has been 
shown to be a master regulator of oxygen homeostasis.  A splice variant of HIF-1α, 
HIF-1α785, is missing exon 11 from its oxygen dependent degradation domain. This 
region encodes the lysine that is critical for enhancing HIF-1α degradation.  The role 
of HIF-1α in the progression of human melanoma has not been fully elucidated. 
Here, I show for the first time that in human melanoma, HIF-1α is expressed 
endogenously with no external stimuli under normoxic conditions. In cell lines 
derived from RGP, VGP, and metastatic phases of human melanoma progression, 
 viii 
the relative amounts of HIF-1α and HIF-1α785 mRNA increase as a function of 
malignant progression.  The expression levels have been verified by qPCR and 
western blot.  Overexpression of HIF-1α or HIF-1α785 in SbCl2 cells leads to 
increased anchorage independent growth, with HIF-1α785 having the greater 
impact.  In WM9 cells, inhibition of HIF-1α by siRNA significantly inhibits matrigel 
invasion and anchorage independent growth in soft agar.  These results show that in 
human melanoma, HIF-1α and HIF-1α785 seem to function to increase 
tumorgenicity. 
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REVIEW OF THE LITERATURE – PART I 
MELANOMA  
Melanoma is the most serious form of skin cancer. Melanoma cells derive from 
the skin’s natural defense system to UV light, the melanocyte. Melanocytes absorb UV 
light and in response, produce the pigment, melanin. To defeat the stresses of this 
unique function, the melanocytes are inherently and naturally resistant to apoptosis 
(Soengas and Lowe 2003). Melanoma incidence is increasing at an alarming rate in the 
U.S.  Melanoma accounts for 4% of all skin cancers, but for 79% of all skin cancer-
related deaths in the United States (Melanoma Research Foundation fact sheet 2006).  
Melanoma has several clinical stages. These range from a radial growth phase 
(RGP) → vertical growth phase (VGP) → metastatic melanoma (MM). Radial growth 
phase cells have the ability to grow without differentiation; however, they are non-
tumorigenic in patients and animal models (Satyamoorthy et al., 1999).  They have 
partial growth autonomy (Hussein MR, 2005).  After the accumulation of more genetic 
changes such as overexpression of oncogenes and loss of certain tumor suppressor 
genes, RGP melanoma cells progress to VGP cells.  Vertical growth phase cells have 
acquired the ability to invade into the dermis (Satyamoorthy et al., 1999).  Metastatic 
cells not only have the ability to invade but to also travel to distant sites resulting in 
secondary tumors (Figure 1).  The later stages of the disease are notoriously resistant 
to chemo- and radiotherapy. More investigation is needed to determine targets allowing 
circumvention of survival mechanisms inherent not only to melanoma cells, but also to 
melanocytes (Soengas and Lowe 2003). 
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Figure 1:  Diagram showing the progression from normal human melanocytes to 
metastatic melanoma.  The progression from melanocytic dysplasia to radial growth 
phase represents the initial stage of cancer in human melanoma progression.  Radial 
growth phase cells have very limited anchorage-independent growth capabilities and 
little to no invasion capacity.  Vertical growth phase cells are able to form tumors in 
mice, have increased anchorage-independent growth capabilities and a high level of 
invasion.  Metastatic melanoma cells have acquired the ability to travel to secondary 
sites to form secondary tumors. 
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Figure 1:  Progression from normal human melanocytes to metastatic melanoma. 
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NUCLEAR RECEPTORS 
Nuclear receptors are a superfamily of transcription factors that regulate the 
expression of hundreds of important target genes. These genes can be involved in a 
variety of processes including cell division, organogenesis, homeostasis, and 
reproduction (Wu et al., 2005). This superfamily includes the vitamin D receptors, 
thyroid hormone receptors, retinoid receptors, steroid receptors and several orphan 
receptors (no endogenous ligand known). Nuclear receptors are ligand activated and 
require the sequential recruitment of coactivators to fully induce gene transcription. 
Nuclear receptors allow cells to respond to extracellular signals via the binding of their 
respective ligands (Friedmann et al., 2005). Nuclear receptors have several conserved 
functional domains (Figure 2). Progressing from the N- to the C- terminus are the first 
activation function (AF-1) domain, the DNA-binding domain, a hinge region, as well as a 
ligand-binding domain that includes the second activation function (AF-2) domain (Wu  
et al., 2005).  The AF-1 domain, sometimes referred to as the A/B domain, has 
transactivation activity.  It has highly variable sequences and lengths among nuclear 
receptors and is often the origin of multiple splice variants resulting in different isoforms 
of the same nuclear receptor.  The DNA-binding domain (DBD) is the most highly 
conserved region of the nuclear receptors and is responsible for recognizing and 
binding the receptor’s cognate DNA response element in the target gene's promoter 
region.  The DBD is also responsible for nuclear receptor homo- or heterodimerization.  
The ligand binding domain (LBD) of nuclear receptors also varies between nuclear 
receptors, but the structure of the LBD is common to nearly all of the nuclear receptors.  
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The LBD has 11-13 alpha helices that form a hydrophobic binding pocket to 
accommodate the nuclear receptor ligand. The residues at the bottom of the LBD 
pocket confer specificity, determining whether or not the nuclear receptor will bind its 
specific ligands such as all-trans retinoic acid, vitamin D3, estrogen, etc.  The LBD also 
accommodates binding of the nuclear receptor to heat shock proteins as well as 
coactivators or corepressors and is also responsible for nuclear localization of the 
receptor.  The second activation function (AF-2 domain) at the C-terminal end of the 
nuclear receptor is thought to act as a "flap" that closes back onto the LBD inducing a 
conformational change inhibiting further ligand binding and allowing interaction with 
coactivators (McAdara J., 2000). 
PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS  
Peroxisome Proliferator Activated Receptors (PPARs) are ligand-activated 
nuclear receptors. They belong to the subfamily of nuclear receptors termed orphan 
receptors. They were first shown to be responsive to a class of chemicals called 
peroxisome proliferators.  Peroxisomes are cellular organelles that are involved in the 
removal of molecular O2 and the breakdown of H2O2.  Other functions of peroxisomes 
include fatty acid oxidation, cholesterol biosynthesis, and glycerolipid synthesis 
(Vamecq et al., 1999).  Peroxisome proliferators were shown to cause an expansion of 
the population of peroxisomes in the livers of rats (Issemann and Green 1990). The 
PPARs have been shown to regulate a myriad of target genes involved in several 
biological processes such as inflammation and the immune response, cell proliferation, 
cell differentiation, angiogenesis, and lipid and glucose metabolism (Friedmann et al., 
2005). 
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There are 3 isotypes of PPAR: PPARγ, PPARα, and PPARβ/δ. Each isotype is 
encoded by a different gene, and has specific functions as well as specific patterns of 
tissue distribution. PPARs have been localized mainly to the liver where there is a high 
fatty acid metabolism, but have also been reported to be expressed in heart, B and T 
lymphocytes (Jones et al.,  2002), fat, kidney, vascular smooth muscle and in 
keratinocytes (Westergaard et al., 2001). PPARs have the typical nuclear receptor 
functional domains; however, each isotype has a distinctive ligand binding domain. 
PPAR ligand binding induces conformational changes which stabilize their interaction 
with coactivators and destabilize their interactions with corepressors. The three PPARs 
have ligand binding domains that are significantly larger than that of other ligand-
activated nuclear receptors. The length of the ligand binding domain of the PPARs is 
~1300 Å. Of this 1300 Å, only 30-40% is occupied by ligand (Xu et al., 2001). It is 
thought that the large size of the ligand binding domain explains why the PPARs can 
bind to multiple natural and synthetic ligands. Even though promiscuous, there still 
remain structural determinants of each PPAR isotype in their respective ligand binding 
domains.  
The ligand binding domain of the PPARs also facilitates their heterodimerization 
with the receptor for 9-cis retinoic acid, retinoid X receptor (RXR). Once ligand is bound 
to the PPAR, there is a conformational change that enables this heterodimerization 
(Friedmann et al., 2005). This heterodimerization is necessary for the PPARs to 
recognize and bind to their DNA response elements within their target genes’ promoter 
regions. The PPAR:RXR heterodimer recognizes a Peroxisome Proliferator Response 
Element (PPRE) consisting of a direct repeat (DR) of the hexameric sequence 
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AGGTCA with 1 nucleotide between the repeats. The ligand for the RXR is not required 
for the transcriptional activation of the PPAR:RXR heterodimer; however if present, it 
has been shown to have a synergistic effect in combination with a PPAR ligand 
(Kliewer, S.A. 1992). In the absence of ligand, the PPAR:RXR heterodimer is 
associated with corepressors which inhibit its ability to activate gene transcription (Wahli 
W., 2002).  
PPARγ  
Peroxisome Proliferator Activated Receptor γ has a molecular weight of ~56kD. 
The gene encoding PPARγ is located on human chromosome 3p25. There are two 
isoforms, PPARγ1 and PPARγ2, resulting from 4 splice variants of the PPARγ gene. 
Splice variants 1, 3, and 4 encode the same PPARγ1 isoform. Splice variant 2 encodes 
the PPARγ2 isoform. PPARγ2 has a longer and distinct N-terminus relative to PPARγ1.  
Natural Ligands of PPARγ  
Essential fatty acids are required in the human diet and can neither be 
synthesized nor derived from other fatty acids. There are two families of essential fatty 
acids: Omega-3 (ω-3) and Omega-6 (ω-6). These essential fatty acids are modified to 
form lipoxins, resolvins, lipid rafts, and the eicosanoid family of oxygenated hydrophobic 
molecules.  
Most human eicosanoids are derived from arachidonic acid, a metabolite of 
linoleic acid. Arachidonic acid can feed into either the 5-lipoxygenase pathway or into 
the cyclooxygenase (prostanoid) pathway. The 5-lipoxygenase pathway results in the 
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Figure 2:  Structural diagram of nuclear hormone receptor domains.  The variable 
NH2-terminal region (A/B) consists of the ligand-independent AF-1 transactivation 
domain. The highly conserved DNA-binding domain (C) is responsible for response 
element recognition and binding. A variable linker region (D) is connected to the 
conserved E/F region that contains the ligand-binding domain, the dimerization surface, 
and the ligand-dependent AF-2 transactivation domain.
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Figure 2:  Structural diagram of nuclear hormone receptor domains.   
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formation of the leukotriene family of eicosanoid lipid molecules. The cyclooxygenase 
pathway results in the formation of prostaglandin, prostacyclin, and thromboxane lipid 
molecules. 
PPARγ can be activated by long chain polyunsaturated fatty acids (PUFAs), fatty 
acid components of oxidized low density lipoproteins (LDLs), as well as certain 
metabolites derived from the cyclooxygenase and lipoxygenase pathways i.e., 15-
deoxy-D-12,14-prostaglandin J2 (PGJ2) and 15-S-hydroxyeicosatetraenoic Acid (15-S-
HETE), respectively.  PGJ2, a metabolite of the PGD2 branch of the cyclooxygenase 
pathway, is thought to be the most potent endogenous ligand for PPARγ (Forman et. al., 
1995).  PGJ2 was shown to directly interact with PPARγ in 1995 by Kliewer et. 
al.(Kliewer et al., 1995). Leukemia cell lines (HL-60) treated with PGJ2 showed a 
significant decrease in cellular proliferation and DNA synthesis (Yamakawa-Karakida et 
al., 2002). In lung cancer cell lines, A549, H345, and N417, 72-hour 4 µmol/L PGJ2 
treatment was shown to inhibit their growth by 50%, 90%, and 85% respectively (Avis et 
al., 2005). However, PGJ2 has also been reported to be non-specific for PPARγ.  Co-
treatment experiments in macrophages were conducted with a competitive inhibitor (a 
thiazolidinedione (TZD) compound, AD-5075) which could bind PPARγ but not induce 
any anti-inflammatory effects. When this inhibitor was used at a concentration that 
would have all but completely displaced any PGJ2 binding, PGJ2 treatment exhibited the 
same anti-inflammatory effects as those seen in control cells lacking the competitive 
inhibitor (Thieringer et al., 2000). It was also shown that in PPARγ-deficient 
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macrophages, PGJ2 treatment inhibited PMA-induced IL-6 production at similar levels 
compared to the PPARγ-wild type macrophages (Moore et al., 2001).  
15-S-HETE was shown to activate PPARγ-dependent transcription in PC3 
prostate cancer cells as well as in DU-145 cells (Shappell et al., 2001). Also, when 
compared to a known synthetic PPARγ agonist, BRL49653 (rosiglitazone), 15-S-HETE 
was also able to induce a dose-dependent inhibition of soft-agar colony formation of 
PC3 cells (Shappell et al., 2001).  
Lysophosphatidic acid (LPA), a lipid mediator which controls mobility, 
differentiation, and cellular growth, is another natural ligand of PPARγ. In competitive 
binding studies, LPA was able to displace [3H]-rosiglitazone (a synthetic ligand for 
PPARγ) from immobilized PPARγ (McIntyre et al., 2003). LPA was also shown to be 
able to stimulate a luciferase reporter gene controlled by a PPRE in RAW264.7 cells, a 
macrophage-like cell line. Co-transfection with PPARγ enhanced the effect of LPA on 
the PPRE reporter gene luciferase activity (McIntyre et al., 2003). LPA has been shown 
to induce the atherosclerotic plaque precursor, neointimas. This LPA-induced neointima 
production in rat carotid artery tissue was abolished by treatment with the irreversible 
PPARγ antagonist, GW9662 (Zhang et al., 2004).  
Synthetic Ligands of PPARγ  
Synthetic ligands for PPARγ include the thiazolidinedione (TZD) class of anti-
diabetic drugs, i.e. Rezulin® (troglitazone) as well as some newly discovered non-
thiazolidinedione compounds. TZD derivatives include BRL49653 (rosiglitazone), 
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pioglitazone, ciglitazone, and englitazone, and troglitazone (Houseknecht et al., 2002; 
Lehmann et al., 1995). TZDs, which are used as insulin sensitizers, are high-affinity 
ligands for PPARγ. It has been found that the most potent of the synthetic ligands for 
PPARγ is rosiglitazone followed by troglitazone, pioglitazone, ciglitazone, and finally 
englitazone (Lehmann et al., 1995). Rezulin® has been shown to bind to PPARγ with 
very high affinity Kd = 40nM (Spiegelman B., 1998). Rezulin®’s effects on insulin 
sensitivity in humans has been shown to be mediated through PPARγ interactions by 
Wilson and Cobb in 1996 (Wilson et al., 1996). While Rezulin® was used to treat type 2 
diabetes mellitus, it was determined by the FDA in March 2000 that it had toxic effects 
on the liver, relative to other thiazolidinedione derivatives rosiglitazone (Avandia®) and 
pioglitazone (Actos®) and was subsequently pulled from the market.  
RWJ-348260 is a very potent non-TZD synthetic ligand for PPARγ. Using a 
PPARγ-Gal4 chimera reporter assay, RWJ-348260 induced PPARγ reporter gene 
transcription with similar effectiveness to rosiglitazone (Rybczynski et al., 2004). RWJ-
348260 was shown to bind to PPARγ with a binding affinity of Kd = 216 ± 99 nM, similar 
to that of rosiglitazone, Kd = 242 ± 22 nM. In vivo, this compound is an insulin 
sensitizer. It improved glucose tolerance as well as reduced glucose, insulin, and 
HbA1c levels in diabetic animals (Rybczynski et al., 2004).  
Recently, a new synthetic non-TZD PPARγ agonist has been found. T33, 
formerly called T11, is a benzopyran derivative. T33 was shown to be able to activate a 
human PPARγ based reporter gene assay with an EC50 value of 19 nmol/L (Hu et al., 
2006). There was a dose dependent reduction in blood glucose levels which was even 
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more significant than what rosiglitazone was able to accomplish in ob/ob mice (Hu et al., 
2006). This study also showed that T33 treatment resulted in a marked improvement in 
oral glucose tolerance and insulin tolerance in the ob/ob mice.  
PPARγ Antagonists  
The most extensively studied aspect of PPARγ has certainly been its ability to 
treat type II diabetes via the TZD agonists’ ability to enhance insulin sensitivity and 
lower blood glucose and lipid levels. However, there are negative side-effects to these 
treatments. PPARγ activation can increase adipocyte differentiation and therefore 
weight gain in these patients. There are PPARγ modulators that can potentially have 
both anti-obesity as well as anti-diabetic effects. These modulators are more often than 
not PPARγ antagonists.  
There have been a number of PPARγ antagonists synthesized to date including 
GW9662, bisphenol-A-diglicidyl ether (BADGE), PD 068235, LG 100641, GW0072 
(partial agonist/antagonist), and recently SR-202 [dimethyl α-(dimethoxyphosphinyl)-p-
chlorobenzyl phosphate]. GW9662 is an irreversible antagonist for PPARγ (Gupta et al., 
2001). The mechanism of GW9662 antagonism is covalent modification of a cysteine 
residue (#285) in the LBD of PPARγ (Leesnitzer et al., 2002). GW9662 has been shown 
to have a 10-fold more potent binding to PPARγ than to PPARα, and a 600-fold more 
potent binding to PPARγ than to PPARδ (Leesnitzer et al., 2002).  
Another PPARγ antagonist is BADGE (Yamauchi et al., 2001). BADGE was 
shown to inhibit the transactivation of PPARγ by 70% and to significantly decrease the 
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expression of PPARγ target genes such as CD36 (Yamauchi et al., 2001).  
PD 068235 is a PPARγ specific antagonist shown to cause a dose-dependent 
decrease in rosiglitazone-stimulated PPARγ transactivation with an IC50 of 0.82 µM 
(Camp et al., 2001). Co-incubation of rosiglitazone with increasing concentrations of PD 
068235 resulted in a dose-dependent decrease in the recruitment of the coactivator 
SRC-1 to the PPARγ receptor (Camp et al., 2001). A hallmark of TZD-induced PPARγ 
activation is the adipocyte differentiation which has been demonstrated in several 
preadipocyte cell lines. PD 068235 was able to antagonize rosiglitazone-stimulated 
adipocyte differentiation in vitro (Camp et al., 2001).  
LG100641 binds to PPARγ and displaces the TZDs from the receptor but does 
not activate transcription of its target genes. LG100641 antagonizes TZD-induced 
adipocyte differentiation while retaining the ability to stimulate insulin-mediated glucose 
uptake in the adipocytes (Mukherjee et al., 2000). It is thought that this antagonism is a 
result of LG100641 binding inhibiting the recruitment of the coactivator SRC-1 to the 
PPARγ LBD (Mukherjee et al., 2000).  
GW0072 is a partial agonist/antagonist for PPARγ (Oberfield et al., 1999). 
GW0072 was shown to activate up to 15-20% of rosiglitazone-induced levels of reporter 
activity of a PPARγ-Gal4 chimera plasmid. GW0072 was also shown to be able to 
displace the corepressor NCoR from the PPARγ LBD, but was unable to adequately 
recruit the coactivators SRC-1 or CBP. Even though GW0072 is able to partially induce 
PPARγ-Gal4 chimera reporter gene activity, it does not allow PPARγ to induce 
adipocyte differentiation in preadipocyte cell lines that were either treated or untreated 
 15 
with rosiglitazone; hence it is termed a partial agonist/antagonist specific for PPARγ 
(Oberfield et al., 1999).  
SR-202 was shown to be a specific antagonist of PPARγ that could have both 
antidiabetic as well as antiobesity activity. SR-202 selectively modulated PPARγ 
transcriptional activity measured in HeLa cells using a PPRE-based transcriptional 
reporter assay (Rieusset et al., 2002). SR-202 is able to block adipocyte differentiation 
induced by either TZDs, dexamethasone, insulin, or 3-isobutyl-1-methylxanthine 
(IBMX). In vivo, SR-202 has been shown to block PPARγ activity, thus resulting in a 
decrease in fat deposits and an increase in insulin sensitivity (Rieusset et al., 2002).  
PPARγ is required for development  
Inactivation of both alleles of PPARγ has been shown to be embryonic lethal. 
PPARγ deficient CB6F1 mouse embryos die in utero at E9.5-E10 (Rosen et al., 2002; 
Barak et al., 1999). PPARγ heterozygotes were able to survive, but were shown to have 
increased tumor susceptibility when treated with DMBA (7,12-
dimethylbenz[a]anthracene), a chemical known to be able to induce tumor formation at 
various locations in normal animals. DMBA caused increased tumor formation at every 
time point between 2-16 weeks in PPARγ heterozygotes compared to PPARγ wild type 
animals (Nicol et al., 2004).  
The CRE/loxP system was used to determine the effects of a conditional 
disruption of PPARγ (Akiyama et al., 2002). The resulting effect was a nearly complete 
deletion of the targeted PPARγ exon 2 which led to a loss of full-length PPARγ mRNA 
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and protein. There was lower expression of genes encoding lipoprotein lipases as well 
as CD36 and LXRα in the PPARγ null macrophages compared to the PPARγ wild type 
macrophages (Akiyama et al., 2002). The CRE/loxP system was also used to determine 
the effect of the loss of PPARγ in mammary development in mice (Cui et al., 2002). This 
loss neither affected mammary development, nor did it lead to increased spontaneous 
tumor formation in the mice (Cui et al., 2002).  
REGULATION OF PPARγ  
Transcriptional level  
The human PPARγ gene is comprised of nine exons and covers over 100 
kilobases of genomic DNA (Fajas et al., 1997).  The PPARγ promoter region contains a 
C/EBP site (Saladin et al., 1999).  Both C/EBPβ and C/EBPδ have been shown to 
activate the transcription of PPARγ (Saladin et al., 1999; Wu et al., 1995).  
Another transcriptional regulator of PPARγ is Adipocyte Differentiation and 
Determination factor 1, independently cloned also as Sterol Regulatory Element Binding 
Protein 1 (ADD-1/SREBP-1).  SREBP-2 also has a binding site within the PPARγ 
promoter (Fajas et al., 1999).   This family of SREBP transcription factors binds to two 
E-box sequence elements either within the PPARγ promoter or 5’ to the promoter 
sequence (Fajas et al., 1999).  It was shown that overexpression of this family of 
transcription factors in HepG2 cells significantly increased PPARγ mRNA levels. 
TGFβ treatment of Human Aortic Smooth Muscle Cells (HASMC) was shown to 
stimulate PPARγ mRNA expression at early time points (30 minutes – 1 hour).  This 
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effect was shown to be mediated by the ERK/Egr-1 signaling pathway since both 
pharmacological inhibition of the MEK/ERK pathway, as well as overexpression of 
NAB2 (a selective repressor of Egr-1) resulted in the abrogation of early induction of 
PPARγ mRNA expression upon TGFβ treatment (Fu et al., 2003).  However, TGFβ 
treatment was shown to have a biphasic effect on PPARγ mRNA expression.  After the 
initial early increase, at 6 hours – 12 hours, there was a marked inhibition of PPARγ 
mRNA expression, and at 24 hours, expression was completely inhibited.  This late-
repression effect was shown to be mediated by AP1 and Smad3 (Fu et al., 2003). 
PPARγ transcriptional inhibitors were discovered utilizing engineered activator- 
and repressor- zinc finger proteins (ZFPs).  These are engineered from the C2H2 family 
of ZFPs to bind with high affinity and specificity to any number of DNA sequences 
(Desjarlais, J and Berg 1992; Greisman, H and Pabo 1997).  By combining a functional 
transcription repressor regulatory element from KRAB with a customized DNA binding 
domain directed at the endogenous PPARγ chromosomal loci, it was found that the 
engineered six-finger ZFP, ZFP55, was able to inhibit the expression of PPARγ mRNA 
in the adipogenic mouse 3T3-L1 cell line (Ren et al., 2002). 
Post-translational Regulation 
 PPARγ has been shown to be regulated at the protein level by several 
mechanisms including phosphorylation, ubiquitination, and nitration.  PPARγ activity can 
be down-regulated by phosphorylation of multiple serine residues including serine 82, 
serine 84, serine 110, and serine 112. 
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 Serine 82 phosphorylation of PPARγ by JNK was shown to negatively regulate 
PPARγ activity in vitro in 293T cells (Camp et al., 1999).  When Ser82 was mutated to 
Ala, the MAPK-induced phosphorylation of PPARγ was abolished in 293T cells (Camp 
et al., 1999).  EGF treatment, in vivo, resulted in phosphorylation at Ser82 leading to a 
reduction in PPARγ transcriptional activity (Camp et al., 1999).  Serine 84 was shown to 
be phosphorylated by ERK2 and JNK leading to the repression of PPARγ transcriptional 
activity in JEG-3 cells (Adams et al., 1997).  Serine 110 was shown to be 
phosphorylated by MAPK in adipocytes, again resulting in an inhibition of PPARγ 
transcriptional activity (Hu et al., 1996).  Serine 112 is phosphorylated by ERK (Shao et 
al., 1998).  A constitutively active PPARγ mutant was produced by mutating the Ser112 
to Asp resulting in a decrease in ligand binding as well as coactivator recruitment (Shao 
et al., 1998).  Phosphorylation of Ser112 is thought to be important in regulating the 
conformation of the unliganded receptor, thus altering the ability of PPARγ to bind ligand 
efficiently. 
 In addition to phosphorylation, PPARγ has been shown to be modified at the 
post-translational level by ubiquitination which ultimately leads to its degradation via the 
proteasomal pathway (Hauser et al., 2000).  Ligand activation of PPARγ was shown to 
enhance its ubiquitination (Hauser et al., 2000). 
 Nitration is another post-translational modification of PPARγ.  Several tyrosine 
residues in PPARγ were shown to be nitrated in response to TNFα, lipopolysaccharide 
or peroxynitrite treatment in RAW 264 macrophages (Shibuya et al., 2002). This 
nitration was shown to inhibit the ligand-induced translocation of PPARγ from the 
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cytosol to the nucleus, thus inhibiting its transactivation potential. 
Corepressors and Coactivators 
 PPARγ has been shown to interact with several coactivators and corepressors 
such as Nuclear Receptor CoRepressor (NCoR), CREB binding protein (CBP), p300, 
Steroid Receptor Coactivator-1 (SRC-1), and Fatty Acid Binding Protein (FABP). 
 NCoR is the major corepressor for PPARγ transactivation (Lavinsky et al., 1998).  
NCoR was shown to interact with the hinge region of PPARγ (Zamir et al., 1997).  Along 
with NCoR, other corepressors interact with PPARγ.  The SRC-1 coactivator binds the 
LBD of PPARγ in a ligand-dependent manner (Zhu et al., 1996).  The coactivator p300 
interacts with the AF-2 region of PPARγ in a ligand-dependent or -independent manner 
(Wang et al., 2001).  Antibodies directed at SRC-1 inhibited TZD-dependent PPRE 
reporter activation in Rat-1 cells (Westin et al., 1998).  Another coactivator for PPARγ is 
FABP.  Both liver FABP and adipose FABP directly interact with PPARγ (Tan et al., 
2002). 
Role of PPARγ in Disease 
 PPARγ is a key regulator of glucose and lipid homeostasis and its physiological 
function has mainly been explored in insulin sensitization, adipocyte differentiation, 
inflammation, and development of atherosclerosis.  PPARγ has also been implicated in 
a number of other conditions including cardiac hypertrophy and more recently, in 
carcinogenesis. 
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 Cancer cells exhibit an inability to balance cell proliferation, apoptosis, and 
differentiation, which ultimately leads to tumor formation.  PPARγ has been suggested 
to play a crucial role in each of these aspects of cancer development.  Activation of 
PPARγ has been shown to either lead to apoptosis, terminal differentiation, or to the 
inhibition of cellular proliferation in several cancer cell lines (Wang et al., 2006). 
 CDKs have been shown to be directly regulated by PPARγ agonists in several 
cancer cell lines. Troglitazone treatment was shown to inhibit the growth of MCF-7 
breast cancer cells (Yin et al., 2001). The mechanism of action in these cells is thought 
to be interference with several proteins that are regulators of pRb phosphorylation such 
as cyclin D1.   Re-introduction of cyclin D1 after troglitazone treatment partially rescued 
these cells from G1 phase cell cycle arrest.  
PPARγ also plays a role in regulating apoptosis. PPARγ activation was shown to 
increase caspase-3 activity in human malignant astrocytoma cells (Chattopadhyay et 
al., 2000).   TNF-related apoptosis inducing ligand (TRAIL)-mediated apoptosis was 
triggered by treating multiple cell types, including SK-OV-3 and HUVEC cells with 
various PPARγ ligands.  Activation of PPARγ was shown to reduce the levels of FLICE- 
Inhibitory Protein (FLIP), a negative regulator of TRAIL-induced apoptosis, by 
increasing its ubiquitination and subsequent degradation (Kim et al., 2002).  
Activation of PPARγ induces differentiation of a number of cancer cell lines. In 
human primary and human metastatic breast adenocarcinomas, PPARγ activation by 
TZD treatment resulted in changes in the cell’s gene expression pattern to one closely 
resembling that of a more differentiated state (Mueller et al., 1998).  In T24 bladder 
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cancer cells, troglitazone was shown to increase the endogenous PPARγ target gene A-
FABP, Adipocyte – Type Fatty acid Binding Protein (A-FABP), a well known marker of 
differentiation in these cells (Guan et al., 1999).  
PPARγ has been shown to play a role in angiogenesis.  PPARγ knockout mice 
die as embryos at ~ E10 in part due to deficient placental vascularization (Barak et al., 
1999). Rosiglitazone-induced PPARγ activation has been shown to decrease vascular 
endothelial growth factor (VEGF), the major regulator of angiogenesis, production in 
LLC cells (Panigrahy et al., 2002).  
While the majority of reports suggest PPARγ to be a tumor suppressor, there are 
a number of studies showing that it could have an opposite effect in some cancers.  
Multiple in vivo studies have shown that introducing TZDs into mim mice (mutation in 
the APC gene) led to a significant increase in both small and large colon 
adenocarcinomas (Saez et al., 1998; Lefebvre et al., 1998). 
Transgenic mice expressing high levels of PPARγ were mated with transgenic 
mice that expressed the mouse mammary tumor virus polyoma middle T and the 
offspring were shown to have an increased incidence of breast cancer formation (Saez 
et al., 2004).  
Role of PPARγ in melanoma 
 Expression and effect of ligand activation of PPARγ has been studied in human 
melanoma.  Both WM35, an early stage melanoma, and A375, a metastatic melanoma 
cell line, have been reported to express PPARγ mRNA and protein.  While one study 
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concluded that the growth of A375 cells was inhibited by ciglitazone (Placha et al., 
2003), another showed that the proliferation of A375 cells was unaffected by this 
compound (Nunez et al., 2006).  Rosiglitazone has been shown to inhibit colony 
formation and induce apoptosis in A375 cells. This study also revealed that 
rosiglitazone induced differentiation in the A375 cells (Liu et al., 2006). 
PPARα 
 PPARα has a molecular weight of ~52 kD. The gene has six coding exons and is 
located on chromosome 22 in humans (Entrez Nucletide Gene).  Active PPARα has 
been shown to increase lipid catabolism and decrease circulating lipid concentrations 
PPARα has also been shown to play some role in glucose metabolism (Knauf et al., 
2006). 
Natural Ligands of PPARα 
 PPARα is known to be activated by fatty acids and their metabolites. It has been 
shown that long-chain fatty acids and eicosanoids are more potent ligands for PPARα 
than even its strongest synthetic ligand, WY-14643 (Murakami et al., 1999). This study 
showed that the fatty acids and eicosanoids were able to directly bind the LBD of 
PPARα. Other studies have shown that mono- and polyunsaturated fatty acids at 
physiological concentrations can also directly bind PPARα (Kliewer et al., 1997). 
 Several arachidonic acid metabolites serve as ligands for PPARα. Leukotriene 
B4 (LTB4) activates PPARα and is thought to be the natural ligand for PPARα (Gupta et 
al., 2001).  LTB4 has been shown to bind to PPARα with a Kd in the nanomolar range, 
 23 
while 8-(S) HETE has also been reported to be a natural ligand for PPARα (Lin et al., 
1999). 
Synthetic ligands for PPARα 
 The major class of synthetic ligands for PPARα is the fibrate hypolipidemic drugs.  
Fibrates are amphipathic carboxylic acids. They are indicated for the treatment of 
several metabolic disorders such as high cholesterol. Some examples of fibrates are 
bezafibrate, ciprotibrate, gemfibrozil, fenofibrate, and clofibrates. 
 The major non-fibrate synthetic agonist for PPARα is WY-14643.  WY-14643 is a 
well known peroxlsome proliferator having effects on DNA replication via PPARα 
(Peters et al., 1997). Results show that PPARα null mice, when fed a diet containing 
0.1% WY-14643 exhibited no hepatocarcinomas while 100% of PPARα +/+ mice 
showed multiple lesions (Peters et al., 1997). 
 GW7647 has been recently reported to be a very potent and selective PPARα 
agonist. It was shown to have ~ 200-fold selectivity for PPARα over both PPARγ and 
PPARδ (Brown et al., 2001), 
PPARα Antagonists 
 The major antagonist for PPARα is MK886. Upon treatment with WY-14643, 
MK886 treatment inhibited the activation of PPARα by 80% in A549 cells (Kehrer et al., 
2001). MK886 had only minimal effects on PPARδ or PPARγ activity.  
 Other inhibitors for PPARα include some acyl – CoA esters.  Palmitoyl – CoA 
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was shown to bind PPARα and compete with WY-14643 for binding to this receptor 
(Elholm et al.,  2001).  Acyl-CoA esters were shown to directly induce PPARα 
conformational change and are thought to be the endogenous regulators of PPARα 
activity. 
PPARα Knockouts 
 Mice that lack expression of PPARα exhibit no typical peroxisome proliferation in 
response to treatment with clofibrate or WY-14643 (Lee et al., 1995). Also, PPARα null 
mice challenged with a diet known to induce insulin resistance were protected from this 
effect. These mice, however, did show increased fat deposits (Guerre-Millo et al., 2001). 
Regulation of PPARα 
 The promoter region of PPARα has seven SP- 1 binding sites (Gearing et al., 
1994). Coup – TFII and HNF4 share a binding site within the PPARα promoter (Pineda-
Torra et al., 2002).  While overexpression of HNF4 increased PPARα promoter activity, 
overexpression of Coup-TFII decreased the activity of the PPARα promoter. 
 Other negative regulators of PPARα expression are some cytokines, such as 
TNF-α and IL-6, and some members of the STAT family of proteins, including STAT5 
(Zhou et al., 1999). 
Post – translational PPARα control 
 PPARα undergoes phosphorylation and ubiquitination (Shalev et al., 1996). The 
phosphorylation of PPARα can be induced by several mechanisms/factors.  Unlike 
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PPARγ, where phosphorylation usually means a decrease in activity, phosphorylation 
can serve to activate PPARα transcriptional activity. 
 PPARα is phosphorylated by MAPK, resulting in transcriptional activation in 
insulin-treated HepG2 cells (Juge – Aubry et al.,1999). This phosphorylation of serine12 
and serine21 is thought to induce a conformational change which could bring about the 
dissociation of the corepressors, NCoR or SMRT, thus increasing transcriptional 
activation of PPARα. This phosphorylation results in ligand independent activation of 
PPARα.  Regulation was further enhanced when fibrate ligand was added to the cells 
(Judge – Aubry et al., 1999).  
 p38 MAPK can also phosphorylate PPARα. This phosphorylation serves to 
increase the transcriptional activity of PPARα through conformational change, allowing 
interactions with the coactivator PGC-1 (Barger et al., 2001).  
 Stimulation of protein kinase A (PKA) activity has also been shown to activate 
PPARα in the absence of ligand via phosphorylation. This activation was mainly 
dependent on an intact AF-2 domain. Phosphorylation by PKA was shown to increase 
the stability of the PPARα:DNA interaction resulting in increased transcriptional activity 
(Lazennec et al., 2000). 
 Recently, PKCα and PKCβII have been shown to phosphorylate PPARα.  
Phosphorylation sites were mapped to serines 179 and 230.  PKC phosphorylation acts 
as a switch that converts PPARα from a transcriptional activator to a repressor 
(Blanquart et al., 2004).   
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 PPARα is ubiquitinated and subsequently degraded by the proteasome. Ligand 
binding was shown to decrease the ubiquitination and extend the half life of PPARα 
(Blanquart et al., 2002). 
Role of PPARα in disease  
 PPARα has been reported to play a major role in transcriptional regulation of the 
enzymes involved in the β-oxidation of fatty acids (Barger et al., 2001). In cardiac 
metabolism, PPARα has been shown to regulate fatty acid uptake and oxidation (Barger 
et al., 2001). In contrast to PPARγ, PPARα can not differentiate fibroblasts into 
adipocytes (MacDougald OA and Lane 1995).  PPARα agonists such as fibrates have 
been shown to lower cholesterol levels by increasing lipoprotein lipase expression in 
liver and muscle (Schoonjans et al., 1996).  The metabolism of the reverse cholesterol 
transport vehicle, HDL, is highly dependent on PPARα activity.  Fibrate treatment 
results in HDL apolipoprotein gene activation leading ultimately to protection from 
atherosclerosis (Lefebvre et al., 2006).  Active PPARα has been shown to play a role in 
inflammation, serving to decrease cytokine activity (Kleemann et al., 2003).  Active 
PPARα plays a role in human breast cancer cell proliferation.  PPARα agonists WY-
14643 and clofibrate increased the proliferation of both MCF-7 and MDA-MB-231 cells 
(Suchanek et al., 2002).  Primary rat liver cultures transiently transfected with human 
PPARα were shown to have decreased nafenopin-induced apoptosis relative to control 
cells (Roberts et al., 1998). 
The role of PPARα in human melanoma remains to be determined.  One study 
showed that WY-14643 had no effect on the growth of A375 human metastatic 
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melanoma cells (Nunez et al., 2005).  Other investigators determined that fenofibrate 
was able to inhibit the migration of both B16F10 mouse melanoma cells and SK-Mel 28 
human vertical growth phase melanoma cells.  This inhibition of migration was restored 
when cells were treated with the PPARα antagonist, MK886 (Grabacka et al., 2006). 
PPARδ 
 PPARδ is the least studied of the three PPAR subtypes.  PPARδ has a molecular 
weight of ~48kD.  In humans, the gene coding for PPARδ is located on chromosome 6.  
PPARδ has been shown to have ubiquitous tissue distribution.  It has been reported to 
be expressed in spleen, brain, macrophages, heart, adipose, muscle, placenta, lung, 
and intestine (Fredenrich and Grimaldi 2004).  One of the proposed roles of PPARδ is 
that it reportedly plays a role in the regulation of fatty acid oxidation (Frendenrich and 
Grimaldi 2004).  The activation of PPARδ was shown to reverse the main features of 
metabolic X syndrome in mice and monkeys.  Some of these effects were a dose-
dependent rise in serum high density lipoprotein cholesterol and lowering the levels of 
small-dense low density lipoprotein, fasting insulin and fasting triglycerides (Fredenrich 
and Grimaldi  2004). 
Natural ligands of PPARδ 
 PPARδ can be activated by unsaturated or saturated long-chain fatty acids, some 
eicosanoids, prostacyclin, and retinoic acid (Amri et al., 1995; Hertz et al., 1996; 
Fredenrich and Grimaldi 2004).  The triglyceride components of native very low-density 
lipoproteins (VLDLs) are also able to activate PPARδ. 
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Synthetic ligands of PPARδ 
 There are several synthetic ligands for PPARγ and PPARα; however, there is 
very limited information on specific synthetic agonists for PPARδ.  The major synthetic 
agonist for PPARδ is GW501516, a very high affinity ligand with a Ki = 1.1 ± 0.1 nM.  
GW501516 was administered to a rhesus monkey model of metabolic X syndrome in 
which the lipid profile is representative of that seen in similarly afflicted humans.  One 
hundred nM GW501516 treatment resulted in an increase of cholesterol efflux from 
cells.  This effect was attributed to increased PPARδ activity leading to increased 
transcription of ABCA1, a reverse cholesterol transporter (Oliver Jr. et al., 2001).  
Similar treatment also resulted in a decrease in serum levels of small-dense low-density 
lipoprotein, fasting insulin, and fasting triglycerides.  GW501516 produced a dose-
dependent lowering of fasting triglycerides, with a 56% decrease at the 3.0 mg/kg dose 
(Oliver Jr. et al., 2001). 
 Another high affinity ligand for PPARδ is GW0742.  This agonist has an EC50 of 
1.1 nM with a 1000 fold higher selectivity for PPARδ over both PPARα and PPARγ 
(Sznaidman et al., 2003).  GW0742 stimulation of PPARβ/δ was found to selectively 
induce keratinocyte terminal differentiation and inhibit their proliferation in vivo (Kim et 
al., 2006). 
PPARδ knockouts 
 The vast majority of PPARδ -/- mouse embryos die at a very early stage due to a 
placental defect.  The survivors showed a significant reduction in fat mass (Peters et al., 
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2000; Barak et al., 2002). 
Regulation of PPARδ 
Transcriptional Regulation of PPARδ 
 The PPARδ promoter contains Tcf-4 binding sites and AP-1 elements (Entrez 
Gene).  The AP-1 elements may allow regulation of PPARδ transcription by TPA or 
TNFα.  TPA induction of PPARδ is mediated through the MAPK pathway (Bryan et. al., 
2006). 
Role of PPARδ in disease 
 Due to the role of PPARδ in regulating lipid metabolism, it is thought to play a 
role in atherosclerosis.  Whether the role of PPARδ in atherosclerosis is antiatherogenic 
or proatherogenic remains to be elucidated (Lee et al., 2003).  One study found that 
PPARδ is a VLDL sensor in macrophages, suggesting it might be involved in the 
accumulation of atherosclerotic plaques (Lee et al., 2003).  Another report revealed that 
the effect on atherosclerosis may depend on whether or not ligand is bound to PPARδ.  
The unliganded PPARδ can sequester BCL-6 allowing progression of the inflammatory 
response.  Liganded PPARδ releases B-cell lymphoma gene 6 (BCL-6), possibly 
resulting in decreased atherosclerosis.  (Lee et al., 2003). 
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REVIEW OF THE LITERATURE 
HIF-1 
 Oxygen is an essential component for cellular viability.  O2 is a critical player in 
mitochondrial respiration, ultimately resulting in the formation of ATP from glucose.  O2 
is the final electron acceptor in the chain of metabolic reactions that result in the 
conversion of glucose to CO2 and H2O.  This aerobic glycolysis generates 32 molecules 
of ATP per molecule of glucose, whereas anaerobic glycolysis only generates 2 
molecules of ATP per molecule of glucose (Wiesener and Maxwell 2003). 
 Consistent with the wide range of physiological functions modulated by O2, the 
O2 sensing system is equally necessary and widespread.  This O2 sensing system was 
uncovered with the discovery that red blood cell production is regulated by 
erythropoietin secretion (Bachman et al., 1993).  Under hypoxic conditions, 
erythropoietin expression was found to increase.  It was also found that this increase 
was regulated by O2 levels in hepatoma cells (Goldberg et al., 1987).  The promoter of 
the erythropoietin gene was found to have a hypoxia-responsive element (HRE) and 
this element was later shown to bind to a heterodimeric transcription factor, hypoxia-
inducible factor 1 (HIF-1) (Wang and Semenza 1995).  It is this transcription factor that 
is the master regulator of oxygen homeostasis. 
 HIF-1 is a heterodimeric protein complex consisting of a ~120kD HIF-1α subunit 
and an ~86kD HIF-1β subunit (Semenza G, 2002).  HIF-1 is responsible for the 
regulation of >60 genes involved in a myriad of cellular functions and physiological 
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processes ranging from angiogenesis to glycolysis to cell proliferation and survival 
(Semenza G, 2002). 
Structure of HIF-1 
 HIF-1 is the most important factor involved in the cells’ adaptation to hypoxia 
(Mazure et al., 2004).  For cells to be able to respond to a range of O2 concentrations, 
HIF-1 must be very tightly regulated.  The structure of the HIF-1 subunits, especially 
HIF-1α, is central to this regulation. 
 There are multiple isoforms of HIF-1α.  HIF-1 can be comprised of either HIF-
1α:HIF-1β, HIF-2α:HIF-1β, or HIF-3α:HIF-1β.  HIF-1α is the full length isoform.  HIF-2α 
is structurally and functionally similar to HIF-1α, however its tissue distribution is much 
more limited.  HIF-3α lacks the transactivation domain found in the HIF-1α and HIF-2α 
subunits.  It is thought that the HIF-3α isoform is a negative regulator of hypoxia-
inducible gene expression by acting as a competitor for the dimerization of HIF-1α/-2α 
to HIF-1β (Jang et al., 2005). 
Both the HIF-1α and HIF-1β subunits of HIF-1 are basic helix loop helix (bHLH) 
and Per Arnt Sim (PAS) domain proteins.  bHLH domains are found in specific DNA- 
binding proteins that act as transcription factors and are usually  60-100 amino acids 
long.  A DNA-binding basic region is followed by two alpha-helices separated by a 
variable loop region.  bHLH regions form homo- and heterodimers (Entrez Conserved 
Domains http://www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml).  The PAS domain was 
named after three proteins that the domain occurs in: Per- period circadian protein, 
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Arnt- Ah receptor nuclear translocator protein, Sim- single-minded protein (Entrez 
Conserved Domains http://www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml). 
The HIF-1α subunit is the “inducible” half of this heterodimer while HIF-1β is 
considered to be constitutively expressed.  The HIF-1α subunit is O2 -labile which is 
stabilized by divalent cations, iron chelators, and hypoxia (Giaccia et al., 2003).  
Currently, it is believed that the HIF-1A gene transcription is not a major point of 
regulation for HIF-1.  It is thought that in most cell lines, under both hypoxic and 
normoxic conditions that the HIF-1A gene transcription is constitutive (Wenger et al., 
1997). 
Regulation of HIF-1 
Transcriptional regulation 
 The human HIF-1A gene, which encodes the HIF-1α protein, consists of 15 
exons.  It is located on chromosome 14 in humans.  There is a splice variant of the HIF-
1A gene, HIF-1A2, which lacks an alternate segment in the 3' coding sequence, 
compared to variant 1, that results in a frame shift. The resulting protein, HIF-1α isoform 
2, is shorter and also has a distinct C-terminus, relative to isoform 1 (Entrez Gene 
http://www.ncbi.nlm.nih.gov/entrez).  The HIF-1B gene encoding the HIF-1β protein has 
22 exons and is located on human chromosome 1.  There are 2 additional splice 
variants for HIF-1B. HIF-1B2 lacks several alternate segments, relative to HIF-1B 
variant 1, which leads to a frame shift.  The resulting protein, HIF-1β isoform 2, is 
shorter and has a distinct C-terminus, compared to HIF-1B variant 1.  HIF-1B3 is 
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missing an alternate in-frame exon in the 5' coding region, compared to HIF-1B variant 
1. This exon deletion results in a protein, HIF-1β isoform 3, that is shorter relative to 
HIF-1β isoform 1 (Entrez Gene http://www.ncbi.nlm.nih.gov/entrez). 
The promoter of HIF-1A belongs to the TATA-less promoter family and has a GC 
rich sequence with several Sp1 binding sites.  There are also several HREs within the 
promoter of HIF-1A which act as HIF-1 cis elements (Iyer et al., 1998).  AP-1 and AP-2 
elements are also present in the promoter of HIF-1A (Minet et al.,1999).  Downstream of 
the initiation site there are several putative transcription factor binding sites including c-
Ets-1, NF-КB, and NF-1 indicating that the transcriptional control of HIF-1A may depend 
on cis acting elements located both upstream and downstream of the transcription start 
site (Minet et al., 1999).  Promoter sequence deletion experiments have shown that the 
core promoter sequence of HIF-1A is from +1bp to -200bp.  The fragment between 
+1bp to -105 bp contains several necessary cis acting elements that control the 
increase in the transcription of the HIF-1A gene in response to hypoxia.  An AP-1 
binding site was found between -29bp to -23bp and could act as a stimulator of HIF-1A 
transcription since AP-1 is shown to be activated under hypoxic conditions (Rajpurohit 
et al., 1996).  Within the sequence spanning -105bp to -201bp there are several AP-2 
cis acting elements.  AP-2 may play some role in the repression of HIF-1A gene 
transcription in response to hypoxia since when this region of the promoter was present 
in the promoter-expression constructs, there was a decrease in HIF-1A gene expression 
down to normoxic levels upon treatment with CoCl2, a hypoxia mimetic (Minet et al., 
1999). 
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Post translational regulation of HIF-1α 
 It is widely held that HIF-1A gene transcription is not necessarily central to the 
regulation of HIF-1 activity.  The post translational modifications, however, have been 
extensively covered and are considered the de facto method of control of HIF-1 
transcriptional activation.  The structure of the HIF-1α protein contributes to this 
complex pattern of post translational regulation. 
 HIF-1α consists of several regulatory domains (Figure 3). The N-terminal bHLH 
and PAS domains are required for both DNA binding and dimerization with HIF-1β 
(Mazure et al., 2004).  The C-terminal region of HIF-1α contains the domains that are 
required for transactivation and degradation.  The oxygen-dependent degradation 
domain (ODDD) within HIF-1α contains amino acids that are modified by several 
mechanisms including hydroxylation, sumoylation, and acetylation in response to O2 
tension (Jiang et al., 1997).  There are also two independent transcriptional activation 
domains within the C-terminal region termed N-TAD and C-TAD.  Between the N-TAD 
and C-TAD domains there is an inhibitory domain (ID), which includes residues 
contributing to the negative regulation of the transactivation domains (Mazure NM 
2004).  Several residues within the C-terminal half of HIF-1α are phosphorylated under 
normoxic and hypoxic conditions by p42/p44 MAPKs resulting in enhanced 
transcriptional activity of HIF-1 (Richard et al., 1999).  S-Nitrosation is another post-
translational modification of HIF-1α.  The S-nitrosation of Cys800 was shown to 
increase HIF-1 transactivation by increasing the interaction of HIF-1 with p300 
(Yasinska and Sumbayev 2003). 
 35 
 Some of these post-translational modifications are involved in regulating HIF-1α 
protein stability; others are involved in controlling HIF-1α activity directly.  These 
methods of control will be discussed in further detail. 
Control of HIF-1α protein stability by hydroxylation 
 The conversion of proline into hydroxyproline requires the activity of iron-
dependent enzymes in reactions requiring oxygen, 2-oxoglutarate, and ascorbate.  Two 
prolines, Pro402 and Pro564, in HIF-1α are hydroxylated by one of three prolyl 
hydroxylase enzymes: PHD1, PHD2, or PHD3.  The activity of these enzymes is 
regulated by cellular O2 concentration (Epstein et al., 2001).  Since these enzymes also 
require iron as a cofactor, iron-mimics such as CoCl2 can act as hypoxia mimetics 
(Mazure et al., 2004).  The cellular localization of the PHD enzymes may play some role 
in their activity as well since PHD1 is nuclear, PHD2 is primarily cytoplasmic, and PHD3 
can be located in either compartment (Metzen et al., 2003).  The hydroxylation of 
Pro402 and Pro564 serves to target HIF-1α for interaction with the Von Hipple Lindau 
(VHL) tumor suppressor.  VHL is the recognition component of an E3 ubiquitin ligase 
that brings about the polyubiquitination of HIF-1α, ultimately resulting in the HIF-1α 
degradation via the proteasome (Maxwell et al., 1999). 
In summary, when cellular O2 concentration is normal (~21%) the PHD enzymes 
are active and can therefore hydroxylate HIF-1α resulting in a decrease in HIF-1α 
protein stability and an increase in its degradation.  Under hypoxic conditions (~2% - 5% 
O2 concentration) this chain of events should not occur, allowing HIF-1α, i.e. the HIF-1 
heterodimer, to turn on the transcription of its target genes.
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Figure 3:  Schematic representation of the functional domains of both HIF-1α full length 
and HIF-1α785.  Upon loss of exon 11 in HIF-1α785, part of the Oxygen Dependent 
Degradation Domain (ODDD) is deleted.  This missing region contains the important 
lysine 532 residue which is acetylated by ARD1 leading to increased stabilization of 
HIF-1α interaction with the von Hippel Lindau tumor suppressor.  This interaction directs 
HIF-1α to the ubiquitin-proteasome pathway for degradation under normoxic conditions.  
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Figure 3:  Schematic representation of the functional domains of both HIF-1α full 
length and HIF-1α 785.
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Control of HIF-1α protein stability by acetylation 
 Lys532 within exon 11 of the ODDD of HIF-1α, has been shown to be acetylated 
by the arrest-defective-1 (ARD1) protein (Jeong et al., 2002).  This acetylation of 
Lys532 results in a stabilization of the interaction between HIF-1α and VHL.  Thus, 
ARD1 acetylation of HIF-1α results in the protein becoming less stable and ultimately 
increasing its degradation via the ubiquitin-proteasome pathway.  Exon 11 is spliced out 
of HIF-1α785, leaving exons 10 and 12 to join in frame.  This results in a variant of HIF-
1α that is thought to be more stable under normoxic conditions due to the ARD1 inability 
to acetylate this critical Lys532.  No Lys532 acetylation leads to a less stable interaction 
between VHL and HIF-1α, which is postulated to result in less degradation via the 
ubiquitin-proteasome pathway (Chun et al., 2003). 
Control of HIF-1α activity by hydroxylation 
 In addition to proline hydroxylation, HIF-1α has also been shown to undergo 
asparaginyl hydroxylation in response to O2 tension.  Under normoxic conditions, the 
factor inhibiting HIF-1 (FIH1) catalyzes this asparaginyl hydroxylation which serves to 
inhibit the interaction of HIF-1α with p300/CBP.  This results in decreased HIF-1 
transcriptional activity under normoxic conditions (Lando et al., 2002). 
Control of HIF-1α by growth factor stimulation 
 While the previous examples of control for HIF-1α are O2 dependent, there are 
O2 independent mechanisms of HIF-1 control as well.  An example of O2 independent 
HIF-1 control is via growth factors.  Hypoxia increases HIF-1α protein expression in all 
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cell types. However, growth factors such as insulin, insulin-like growth factor, and 
epidermal growth factor, only stimulate HIF-1α expression in a cell-type dependent 
manner.  This expression is not dependent on the cellular oxygen concentrations.  
Growth factors activate PI3K or MAPK pathways, which in turn, increase HIF-1α protein 
expression (Fukuda et al., 2002). 
Control of HIF-1α activity by phosphorylation 
 The MAPK p42/p44 is capable of phosphorylating HIF-1α (Richard et al., 1999).  
It was shown that HIF-1α is highly phosphorylated in vivo and that this phosphorylation 
results in a change in the electrophoretic migration pattern of HIF-1α.  HIF-1α induced 
by hypoxia migrates at ~104kD to ~116kD.   In HeLa cells, when HIF-1α was 
immunoprecipitated and then incubated with lambda phosphatase, this resulted in a 
shift of 12kD below the control HIF-1α (no lambda phosphatase treatment) resulting in a 
sharp band at ~104kD on the gel (Richard et al., 1999).  The p42/p44 phosphorylation 
of HIF-1α resulted in an increase in HIF-1 transcriptional activity under normoxic 
conditions. 
Control of HIF-1α activity by sumoylation 
 HIF-1α can be sumoylated by the sumo E3 ligase, RanBP2, in vitro (Mazure et. 
al., 2004).  Sumoylation proceeds similarly to ubiquitination; however, it is not thought to 
target proteins for degradation.  Sumoylation has been shown to regulate protein 
localization and in some instances activation of certain transcription factors (Mazure N 
et al.,2004).  Sumoylation by SUMO-1 has been shown to increase the stability and 
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activity of HIF-1α in vitro (Bae et. al., 2004). 
Control of HIF-1α activity by heterodimerization 
 The dimerization of HIF-1α to HIF-1β is required for HIF-1 transcriptional activity.  
This dimerization can be inhibited by competitive binding of inhibitory molecules.  An 
inhibitory PAS (IPAS) molecule competes with HIF-1β for heterodimerization with the 
HIF-1α subunit under hypoxic conditions.  This IPAS molecule is the third isoform of 
HIF-1α, HIF3α (Jang et al., 2005).  Ectopic expression of IPAS in Hepa 1c1c7 
hepatoma cells was shown to selectively interfere with the induction of genes that are 
up-regulated by hypoxia, including VEGF (Makino et al., 2001).  Overexpression of 
IPAS also resulted in a decrease in tumor growth and tumor vascular density in mice 
(Makino et al., 2001). 
HIF-1 antagonists 
 TX-402, a potent hypoxia-selective cytotoxic agent, was shown to reduce the 
expression of VEGF and glucose transporter type 3 (GLUT-3) under hypoxic conditions.  
The mechanism of TX-402 action in the reduction of the VEGF and GLUT-3 genes 
appears to involve direct suppression of HIF-1α mRNA and protein levels (Nagasawa et 
al., 2003). 
 The National Cancer Institute Diversity Set of 2000 compounds was screened for 
potential HIF-1α inhibitors.  NSC-134754, a semisynthetic analogue of emetine (a 
natural alkaloid) and NSC-643735, a structural analog of actinomycin D aglycone, were 
both shown to have HIF-1 inhibitory effects.  However, NSC-134754 inhibited hypoxia-
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induced HIF-1 activity and HIF-1α protein expression.  Hypoxia-induced expression of 
Glut-1 was also significantly inhibited by NSC-134754.  Both compounds were able to 
inhibit growth factor-induced HIF-1α protein expression (Chau et al., 2005). 
 A screen of 15,000 compounds revealed 3 hits for inhibitors of HIF-1 activity, 
DJ12, DJ15, and DJ30 (Jones and Harris 2006).  None of the compounds were able to 
inhibit HIF-1α protein expression; however they did inhibit hypoxia-induced HIF-1α 
target gene expression.  DJ12 was the only compound that could inhibit these target 
genes in multiple cancer cell lines including breast cancer cells, MDA-468 and ZR-75; 
melanoma cell line MDA-435; and pVHL mutant-renal cancer cell lines RCCR and 786-
0 (Jones and Harris 2006).  The DJ12 induced inhibition of HIF-1α target genes was 
attributed to the inhibition of HIF-1α DNA binding. 
Physiological Roles of HIF-1 
 HIF-1 is operational in all mammalian cell types, while the HIF-1 – VHL – PHD 
system is fully conserved from D. melanogaster to C. elegans to H. Sapiens (Wiesener  
and Maxwell 2003).  The importance of this system is also underscored by the multitude 
of physiological processes that HIF-1 can influence.  These processes include 
erythropoiesis, iron metabolism, cellular glucose transport, glycolysis, angiogenesis, 
regulation of vascular tone, signal transduction, and cell survival (Wenger et al., 2002).  
While there is in vitro data that suggests the possibility that HIF-1 is involved in several 
physiological and pathological processes, current data on the actual role HIF-1 plays in 
vivo is somewhat limited.  In vivo data is limited to the role of HIF-1 in embryonic 
development, erythropoiesis, and cancer. 
 42 
Role of HIF-1 in development 
 In a mouse model, either VHL, HIF-1α, HIF-2α, or HIF-1β knockouts are 
embryonic lethal due to interference with vascular network development (Gnarra et al., 
1997; Ryan et al., 1998; Peng et al., 2000; Maltepe et al., 1997).  Reports of either 
partial knockout or tissue specific knockout of HIF-1α are very few.  One study showed 
that tissue specific knockout of HIF-1α in chondrocytes resulted in failed growth plate 
development (Schipani et al., 2001). 
Role of HIF-1 in ischemia 
 While the actual role that HIF-1 plays in ischemia is difficult to predict, HIF-1 
activation has been detected in certain ischemic conditions.  In mice with oxygen-
induced ischemic retinopathy, HIF-1α levels were shown to be increased in the retina 
(Ozaki et al.,1999).  Brain ischemia also resulted in increased HIF-1α activity.  HIF-1α 
and HIF-1β protein levels were also significantly increased after intraperitoneal injection 
of CoCl2 (Bergeron et al., 2000).  The kidney exhibits an increased potential for 
upregulation of HIF-1 transcriptional activity.  Renal ischemia-induced upregulation of 
HIF-1α has been reported, with the increase in HIF-1α/2α selective with respect to cell 
type and kidney zone, correlating with the known O2 profiles in these areas 
(Rosenberger et al., 2002).  The functional role of this activation is still under 
investigation; however, since increased activation of HIF-1 leads to angiogenesis and 
hypoxia-induced metabolic adaptation, this adaptive response should prevent excessive 
death of kidney cells (Wiesener and Maxwell 2003). 
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Role of HIF-1 in cancer 
 By far, the most extensively studied area of HIF-1 function and regulation at both 
the in vitro and in vivo levels is in cancer biology.  HIF-1 activation compensates for an 
inadequate O2 supply.  Solid tumors have regions of severe hypoxia, especially toward 
their core.  Normal mammalian cells have evolved very sophisticated mechanisms of 
control for HIF-1α.  The need for survival under hypoxic conditions for malignant cells 
nearly always overpowers this tight control of HIF-1 activity.  This survival is 
accommodated by increasing HIF-1 activity, which in turn, increases the transcription of 
genes involved in angiogenesis and metabolic adaptation.  Overexpression of HIF-1α 
and HIF-2α has been shown to be poor prognostic indicators for several tumors (Harris 
et al., 2002).  Monoclonal antibody staining for HIF-1α revealed overexpression in 
several cancers including breast, cervix, brain, ovary, oropharynx, and uterus (Semenza 
G., 2003).  Other reports seemingly show contradictory results for non-small cell lung 
cancer and head and neck cancers, revealing that HIF-1α overexpression correlated 
with decreased mortality (Beasley et al., 2002; Volm and Koomagi 2000).  However, 
these results could not be repeated (Giatromanolaki and Harris 2001; Koukourakis et 
al., 2002).  It seems that while the majority of studies link HIF-1α overexpression and 
activity to enhanced tumor progression, the actual effect may be dependent on the type 
of cancer as well as the stage of the cancer progression (Semenza G., 2003). 
Pancreatic cancer cells, PCI-10, which were overexpressing exogenous HIF-1α 
showed a significant increase in the frequency of xenograft growth post injection 
(Akakura et al., 2001).  This study revealed that transfection of HIF-1α into a series of 
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pancreatic cancer cells that were not expressing HIF-1α at high levels made these cells 
more resistant to apoptosis and also resulted in increased tumorgenicity. 
Hypoxia-induced or exogenous overexpression of HIF-1α directly increased in 
vitro invasion by the human colon adenocarcinoma cells, HCT116 (Krishnamachary et 
al., 2003).  HIF-1α overexpression in tumor xenografts of HCT116 cells resulted in 
increased growth and angiogenesis (Ravi et al., 2000). 
In addition to overexpression of HIF-1α, the inhibition of this subunit has also 
revealed the relevance of HIF-1 to cancer pathology.  Inhibition of HIF-1α activity by 
overexpression of a dominant-negative form of HIF-1α in pancreatic cancer cells, PCI-
43, resulted in an increase in apoptotic cells and a decrease in their ability to form 
tumors in SCID mice (Chen et al., 2003). 
HIF-1α -/- mouse embryonic stem (ES) cells showed significantly impaired 
xenograft vascularization compared to HIF-1α +/+ ES cells.  HIF-1α null ES cells were 
shown to form teratocarcinomas that were only ¼ the size of HIF-1α +/+ ES cells (Ryan 
et al., 1998).  This study also showed that within the HIF-1α -/- tumors, there was a 
significant increase in apoptosis.  Transformed fibroblasts derived from the HIF-1α -/- 
mouse embryos exhibited reduced tumor mass at 16 – 18 days post injection (Ryan et 
al., 2000). 
Inhibition of HIF-2α by siRNA was recently shown to significantly decrease the 
growth of neuroblastoma tumor xenografts in athymic mice.  HIF-2α was shown to 
mediate the chronic response of the cells to hypoxia, while HIF-1α was implicated in the 
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acute hypoxia response (Holmquist-Mengelbier et al., 2006). 
Role of HIF in melanoma 
 While there are over 1,000 articles relating to HIF-1 and cancer, there are 
relatively few articles discussing HIF-1 activity and its effect on human melanoma.  This 
is an area of research that is critical, since it is well known that the skin is considered to 
have a hypoxic microenvironment.  This hypoxic stress is thought to contribute to the 
Ras and Akt-induced transformation of normal human melanocytes (Michaylira and 
Nakagawa 2006).  Akt was only able to transform normal human melanocytes in the 
presence of hypoxia (Bedogni et al., 2005).  This study also shows that inhibition of HIF-
1α using siRNA inhibits the Akt-hypoxia induced melanocyte transformation.  Inhibition 
of HIF-1α expression by rapamycin though mTOR also inhibited melanocyte 
transformation (Michaylira and Nakagawa 2006). 
A recent study investigated the involvement of HIF-1 in uveal melanoma 
migration, invasion and adhesion.  It was found that hypoxia increased migration, 
invasion and adhesion of Mum2B uveal melanoma cells in vitro.  HIF-1α silencing using 
RNAi resulted in a significant decrease in uveal melanoma cell migration, invasion and 
adhesion (Victor et al., 2006). 
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EXPERIMENTAL OBJECTIVE 
This project focused on the effect of transcription factors on the progression of 
human melanoma.  One of the objectives was to elucidate the role of PPARs in cellular 
growth and differentiation in human melanoma cell lines SK-Mel 28, A375, and normal 
human melanocytes HEMn-LP.  The hypothesis was that modulation of the PPARs 
activity and/or expression could lead to a less-tumorgenic phenotype in the human 
melanoma cells.  The first part of this dissertation examined the effects of various PPAR 
agonists on these cell lines.  Also, I determined the endogenous expression levels of 
the PPAR subtypes at both the RNA and protein levels in these cells.  The first part of 
my dissertation work ends with determining the biological effects of PPARα loss-of-
function via siRNA knockdown. 
The second part of this dissertation examines the function of HIF-1 in human 
melanoma progression.  During the course of these experiments, I have found, for the 
first time, that the oxygen-labile subunit of HIF-1, HIF-1α, is present under normoxic 
conditions in the human metastatic cell lines, A375 and WM9.  The hypothesis was that 
an increase in expression of HIF1α or HIF-1α785 in radial growth phase cells would 
render these cells more tumorgenic while a decrease in the expression of HIF-1α in 
metastatic cells would lower their tumorgenicity.  I have shown for the first time that 
there is regulation of HIF-1α at the mRNA level in human melanoma.  qPCR data shows 
that HIF-1α mRNA increases as a function of malignant progression while remaining 
relatively undetectable in normal human melanocytes.  Another objective of the second 
half of my dissertation was to determine the biological effects of siRNA-induced HIF-1α 
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loss-of-function in the human metastatic melanoma cells WM9.  The last part of my 
dissertation work concentrates on the biological effects of HIF-1α gain-of-function in the 
radial growth phase human melanoma cell line, SbCl2. 
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CHAPTER I 
Function of PPARs in human melanoma progression 
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INTRODUCTION 
 Activation of PPARs has been reported to decrease cell growth and stimulate 
differentiation in many cancer cell lines.  However, there have been very few reports of 
the levels of their expression when comparing human melanoma cells to human 
melanoctyes.  The purpose of the following experiments in the first part of my 
dissertation was to characterize the expression and/or function of PPARs in human 
melanoma.  I found that the levels of PPARγ protein expression were ~50% lower in the 
human melanocytes compared to several human melanoma cell lines.  PPARα protein 
expression was between 80-90% lower in normal human melanocytes than in the 
melanoma cell lines, SK-Mel 28 and A375.  I also examined the effect of PPAR agonists 
on proliferation of the human melanoma cells and normal human melanocytes.  I found 
that there was a consistent dose dependent decrease in proliferation in the SK-Mel 28, 
A375, and the normal human melanocytes upon treatment for 48h with the PPARγ 
agonists PGJ2 and troglitazone.  Quantigene® mRNA analysis of PPARα revealed 
significantly higher levels in human melanoma compared to normal human 
melanocytes, correlating to the amount of PPARα protein.  PPARα siRNA treatment 
consistently decreased PPARα mRNA by ~80%, yet there was no significant change in 
morphology, or expression of a PPARα target gene, MCAD.  These data suggest that 
while PPARα is overexpressed in human melanoma relative to normal human 
melanocytes, decreasing its expression has no significant influence on major biological 
properties of the melanoma cells. 
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MATERIALS AND METHODS 
Cell and Culture Conditions 
 SK-Mel 28 human vertical growth phase melanoma cells were obtained from 
American Type Culture Collection (Manassas, VA).  They were grown in a humidified 
atmosphere of 5% CO2 and 95% air at 37°C in Dulbecco’s Modified Eagle’s Medium 
(DMEM).  The DMEM contained 1g/L glucose and was supplemented with 10% bovine 
calf serum (Gibco, Carlsbad, CA), 50U/mL penicillin G and 50ug/mL streptomycin 
sulfate.  A375 human metastatic amelanotic melanoma cells were also obtained from 
the ATCC.  A375 cells were cultured similarly to the SK-Mel 28, with the exception that 
10% fetal bovine serum was used as the supplement (Gibco, Carlsbad, CA).  Normal 
human melanocytes, HEMn-LP (Cascade Biologics, Portland, OR) were grown in 5% 
CO2 and 95% air at 37°C.  They were grown in Media 254 supplemented with 50mL 
human melanocyte growth serum (HMGS) and 1mL penicillin/streptomycin mix (all from 
Cascade Biologics, Portland, OR). 
PGJ2, Ciglitazone, Troglitazone, WY-14643, and LTB4 
PGJ2, ciglitizone, and WY-14643 were obtained from BioMol (Plymouth Meeting, 
PA) and were dissolved in DMSO to a stock concentration of 10mM.  Fresh dilutions of 
each were prepared for each experiment by dilution of the 10mM stock solutions, which 
were stored at -20ºC, with tissue culture media prior to cell treatment.  Equal volumes of 
DMSO were used in the control treated cells.  Troglitazone was obtained from Cayman 
Chemicals (Ann Arbor, MI) and prepared similarly to the aforementioned compounds.  
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LTB4 was purchased from BioMol and was dissolved in 100% ethanol to a stock 
concentration of 10nM and stored under a layer of nitrogen gas.  LTB4 treatment was 
carried out under zero light conditions and the treated cells were protected from light 
until assays were performed.  Fresh sample was prepared for each experiment and any 
remaining solution was discarded.  Equal volumes of ethanol were used to treat the 
control cells.  Forty eight hours after the cells were treated with either of these reagents 
they were assayed as described below. 
Anchorage-Dependent Growth 
All cells were seeded at 5.0 x 105 into 100mm culture dishes.  After 72h, cells 
were treated with or without various PPAR agonists for 48h.  Anchorage-dependent 
growth was determined by either hemacytometric analysis or by crystal violet staining.  
Hemacytometric analysis was carried out as follows:  media was aspirated from the 
plates and they were then washed using PBS.  After PBS aspiration, cells were 
trypsinized for 2 minutes, washed off the plate using the trypsin, pipetted into a 50mL 
centrifuge tube, and brought up in 15mL DMEM + 10% BCS.  Cells were counted suing 
a hemocytometer and corrected for control cell number.  Results are expressed as % 
control in millions of cells.  Experiments are representative of 3 or more independent 
assays.  Crystal violet staining was performed as follows:  Media was aspirated from the 
dishes and cells were fixed with 80% methanol for 1h.  Next, cells were stained using 
0.5% crystal violet for 1h with shaking.  After staining, excess crystal violet was 
removed from the dishes by extensive washing with distilled H2O.  Once excess stain 
was removed, stain was eluted from each dish using 1mL of 10% acetic acid and 250µL 
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of the eluate was read on the spectrophotometer at 570nm.  Results are expressed as 
% control.  Experiments are representative of 3 or more independent assays. 
Relative Melanin Content 
Cells were seeded at 5.0 x 105 cells per 100mm dishes.  After 72h of incubation, 
cells were treated with or without PPAR agonists.  Cells were further incubated for 48h, 
washed with cold PBS, and dissolved in 1N KOH and incubated at 80°C for 1h.  The 
lysate was subsequently centrifuged at 12,000 x g for 10 min and the relative melanin 
concentration of these supernatants was determined by spectrophotometric analysis at 
A462nm and normalized to cell number. 
RT-PCR 
 Total RNA was extracted using Tri-Reagent (Molecular Research Center Inc., 
Cincinnati, OH) as per the manufacturer’s instructions.  RNA integrity was determined 
using the Agilent Bioanalyzer®.  Intact RNA was reverse transcribed to cDNA using the 
Advantage RT-for-PCR kit® (Clonetech) as per the manufacturer’s instructions.  Five µL 
of the resulting cDNA was used in the PCR amplification.  PCR amplification was 
carried out as described by the manufacturer using the Advantage cDNA kit® 
(Clonetech).  PPARγ1 forward primer sequences were 5’-
CCTCGAGGACACCGGAGAG-3’.  PPARγ1 reverse primer sequences were 5’-
CCCTTGCATCCTTCACAAGCATG-3’.  PPARγ2 forward primer sequences were 5’-
GGGTGAAACTCTGGGAGATTCTC-3’.  PPARγ2 reverse primer sequences were 5’-
CCCTTGCATCCTTCACAAGCATG-3’.  PPARδ forward primer sequences were 5’-
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ATGGAGCAGCCACAGGAG-3’.  PPARδ reverse primer sequences were 5’-
CCACCAGCTTCCTCTTCTCA-3’.  All reactions were carried out for 25-30 pcr cycles.  
Typical reaction conditions were 1 min at 94°C; 24-29 cycles at 94°C for 30 sec and 
68°C for 4 min; then 5 min at 68°C for the final extension of products.  PCR products 
were separated by agarose gel electrophoresis using a 1% agarose gel and detected 
using ethidium bromide staining.  Products were visualized by UV light.  Photos were 
taken of the gels and visually analyzed for either the presence or absence of a band at 
the correct molecular weight. 
Quantigene® assay 
 This method of mRNA analysis was developed by Genospectra, Inc. (now 
Panomics Inc.).  This assay allows quantitation of mRNA from either whole cell lysate or 
extracted total RNA.  This assay is based on branched DNA technology.  The desired 
mRNA is hybridized to a gene specific probe set, here, PPARα.  The probe set consists 
of three types of probes: Capture Extender, Label Extender, and the Blocking probe, all 
designed to hybridize to the target mRNA.   Manufacturer supplied protocol was 
followed throughout these experiments.  Briefly, for the whole cell lysate method:  
Lysate from 20,000 cells was loaded in each well of a Quantigene® Capture Plate and 
hybridized to probes specific for PPARα mRNA.  The ratio of PPARα expression 
corrected for β-actin relative to HEMn-LP was calculated.  Extracted total RNA method:  
2ug/10uL total RNA was loaded in each well of a Quantigene® Capture Plate and 
hybridized to probes specific for PPARα mRNA.  The fold change of PPARα siRNA 
treated cells relative to control siRNA treated cells corrected for B-actin was calculated. 
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Western Blotting 
     Nuclear extract from SK-Mel 28, A375, and HEMn-LP was isolated from each cell 
line using the NePER kit® 72 hours after seeding when cells were at ~70% confluence 
(Pierce, Rockford, IL) according to the manufacturer’s protocol.  For MCAD western blot 
analysis, whole cell lysate was isolated from control and siRNA treated SK-Mel 28 cells 
at 48h or 96h post treatment.  Protein concentration was determined using the BCA 
protein assay reagents from Pierce as per the manufacturer’s instructions.  50ug protein 
was separated by SDS-PAGE and transferred to nitrocellulose membranes using the 
BioRAD MiniProtean3® system.  Equal loading was also determined by Ponceau 
staining of the nitrocellulose membranes following transfer.  Blots were blocked using 
ChemiBlocker reagent (Chemicon, Temecula, CA) and probed overnight at 4°C with 
either anti-PPARγ monoclonal (Cell Signaling, Danvers, MA) at 1:1000, anti-PPARα 
monoclonal (Panomics, Inc., Freemont, CA) at 1:250, or anti-MCAD polyclonal at 
1:2000 (Cayman Chemical, Ann Arbor, MI).    Monoclonal mouse secondary IgG 
antibody (GE Healthcare, Piscataway, NJ) or polyclonal rabbit secondary IgG antibody 
(Cell Signaling, Danvers, MA) was applied after three 1x TBS + 0.05% Tween (TBS-T) 
washes.  Blots were incubated with secondary antibody at 1:3,000 for 1h at room 
temperature and subsequently washed 3x with 1x TBS-T.  A final 5 minute wash with 
TBS (no Tween) was performed just prior to incubating the blot with ECL reagent for 
chemiluminescence detection (GE Healthcare, Piscataway, NJ).  Blots were then 
autoradiographed and densitometric analysis was performed.  For PPAR blots, the ratio 
of GAPDH to PPARα or PPARγ is shown. 
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siRNA inhibition of PPARα in SK-Mel 28 VGP melanoma cells 
 SK-Mel 28 cells seeded into 6 well plates at 5.0 x 104 were treated 24h after 
seeding with either 100nM PPARα siRNA or 100nM control non-targeting siRNA 
(Dharmacon, Inc. Lafayette, CO) using the RNAifect® transfection reagent (Qiagen, 
Inc.) as per the manufacturers instructions.  Briefly, siRNA oligos were diluted to a stock 
concentration of 10mM using 1x siRNA buffer (Dharmacon, Inc. Lafayette, CO).  Final 
concentration of siRNA (100 nM) was obtained by diluting stock into the appropriate 
amount of RNAifect® transfection reagent as per product manual.  PPARα inhibition 
was confirmed by Quantigene® analysis at 48 and 96h post transfection.  There was 
~80% decrease in PPARα mRNA relative to PPARα mRNA levels in control siRNA 
treated SK-Mel 28 cells at each time point. 
Statistical Analysis 
       Where applicable, data was analyzed by unpaired, two-tailed t tests.  Statistical 
significance was defined as a p value of 0.05 or less.  All error bars shown represent 
standard error. 
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RESULTS 
Anchorage-Dependent growth in human melanoma and normal human 
melanocyte cell lines treated with PPAR agonists 
 The hypothesis that PPARγ or PPARα activation could lead to a less tumorigenic 
state in human melanoma was initially tested by determining the effects that various 
PPAR agonists had on each of the human melanoma and normal human melanocyte 
cell lines.  To discern which PPAR subtypes might be involved in anchorage-dependent 
growth inhibition, I treated normal human melanocytes, SK-Mel 28 (VGP), and A375 
(amelanotic metastatic) human melanoma cells with or without the PPARγ agonists 
PGJ2, ciglitazone, or troglitazone.  The effects of PPARα activation on anchorage-
dependent growth were observed by treating these cells with or without the PPARα 
agonists WY-14643 or LTB4.  Each cell line was treated for 48h and the growth rates 
were determined by either hemacytometer or crystal violet staining (Figures 4-16).  
Each treatment was performed in triplicate at least 3 times unless otherwise noted.  
Contrary to our original hypothesis, the SK-Mel 28 cells were not significantly growth 
inhibited by any of the PPARγ or PPARα agonists (Figures 4, 6, 7 and 8).  In support of 
our hypothesis, however, I found that the A375 metastatic cells were significantly growth 
inhibited in response to the natural PPARγ agonist, PGJ2 at 10µM (Figure 9) and the 
synthetic PPARγ agonist, troglitazone also at the 10µM concentration (Figure 13).  
Troglitazone treatment also resulted in significant anchorage-dependent growth 
inhibition in the normal human melanocytes at 10µM (Figure 14).  Our hypothesis that 
PPARα activation could lead to a significant decrease in anchorage-dependent growth 
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in these cells could not be supported by our data.  No cell line tested was significantly 
affected by any PPARα agonist used.  In addition to anchorage-dependent growth, 
another marker of cellular differentiation in melanoma is an increase in melanin 
production.  We hypothesized that treatment of the melanin producing cells with the 
PPAR agonists would increase their melanin production, thus indicating a more 
differentiated phenotype.  However, SK-Mel 28 cells treated with PGJ2 exhibited no 
reproducible significant change in melanin production (Figure 5).  Normal human 
melanocytes had no significant reproducible change in melanin production when they 
were treated with the PPARγ agonist troglitazone (Figure 15).   A375 cells are 
amelanotic, therefore no melanin assay was performed.  When treated with PGJ2, the 
normal human melanocytes exhibited no significant reproducible change in anchorage 
dependent growth (Figure 16).    In support of our hypothesis, I found that anchorage-
dependent growth in the A375 human metastatic melanoma cells and the normal 
human melanocytes was significantly affected by PPARγ agonists. 
Expression of PPAR subtype mRNA 
 Since PPAR agonists elicited no significant reproducible effect on anchorage-
dependent growth in SK-Mel 28 cells, and also in light of the fact that no PPARα agonist 
had an effect on any cell line tested, I needed to determine whether or not there was 
expression of the PPAR subtypes in the cell lines.  To determine the levels of PPARγ1, 
PPARγ2, and PPARδ mRNA, RT-PCR was performed in the SK-Mel 28 and A375 cells.  
These results show that PPARγ1, PPARγ2, and PPARδ are all expressed in these cell 
lines (Figure 17).  To determine the relative levels of PPARα in the normal human 
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melanocytes, SK-Mel 28, and A375 cells, the Quantigene® assay was used.  I found 
that PPARα mRNA levels were ~2 fold higher in the SK-Mel 28 cells relative to the 
normal human melanoctyes (Figure 18).  A375 levels of PPARα mRNA were only ~0.14 
fold higher than the levels found in the normal human melanocytes (Figure 18).  To 
summarize, both SK-Mel 28 and A375 cells were positive for PPARγ1, PPARγ2, PPARδ, 
and PPARα mRNA expression.  The normal human melanocytes were only tested for 
PPARα and were positive for this PPAR subtype mRNA.
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Figure 4:   Anchorage-dependent growth study in SK-Mel 28 treated with PGJ2.  
SK-Mel 28 cells (5.0x105) were seeded into each 100mm dish.  At 72h post seeding, 
cells were treated with or without agonist.  The PPARγ agonist, PGJ2, or DMSO vehicle 
(Control) was used to treat SK-Mel 28 cells.  After 48h treatment, cellular growth was 
determined by crystal violet staining as described in materials and methods.  Results 
are expressed as fraction of control.  Experiments were performed in triplicate and 
figure is representative of 3 or more independent assays.  Error bars represent standard 
error.
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Figure 4:  Anchorage-dependent growth study in SK-Mel 28 treated with PGJ2 
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Figure 5:  Melanin production in SK-Mel 28 treated with PGJ2.  SK-Mel 28 cells were 
seeded at 5.0x105 into 100mm dishes.  Seventy two hours later, cells were treated with 
PGJ2 or DMSO vehicle (Control) for 48h.  Cells were subsequently lysed with 1N KOH 
and the lysate was placed in 80ºC water bath.  One hundred µL of cellular lysate was 
loaded into the wells of a 96-well plate and the amount of melanin determined by 
measuring the absorbance at 462 nm.  Results are corrected for cell number and shown 
as fraction of control.
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Figure 5:  Melanin production in SK-Mel 28 treated with PGJ2 
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Figure 6:  Anchorage-dependent growth study in SK-Mel 28 treated with 
ciglitazone.  SK-Mel 28 cells were seeded at 5.0x105 cells per 100mm dish.  At 72h 
post seeding the PPARγ agonist, ciglitazone (Cig) or DMSO vehicle (Control) was used 
to treat the cells.  After 48h of troglitazone treatment, cellular growth was determined by 
hemocytometric analysis.  Cells were counted and corrected for control cell number.  
Results are expressed as fraction of the control.  Experiments were performed in 
triplicate and figure is representative of 3 or more independent assays.  Error bars 
represent standard error. 
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Figure 6:  Anchorage-dependent growth study in SK-Mel 28 treated with 
ciglitazone 
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Figure 7:  Anchorage-dependent growth study in SK-Mel 28 treated with WY-
14643.  SK-Mel 28 cells were seeded at 5.0x105 cells per 100mm dish.  At 72h post 
seeding the PPARα agonist, WY-14643 (WY) or DMSO vehicle (Control) was used to 
treat the cells.  After 48h of WY-14643 treatment, cellular growth was determined by 
hemocytometric analysis.  Cells were counted and corrected for cell number.  Results 
are expressed as fraction of control.  Experiments were performed in triplicate and 
figure is representative of 3 or more independent assays.  Error bars represent standard 
error.
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Figure 7:  Anchorage-dependent growth study in SK-Mel 28 treated with WY-
14643 
 67 
Figure 8:  Anchorage-dependent growth study in SK-Mel 28 treated with 
troglitazone.  SK-Mel 28 cells were seeded 5.0x105 cells per 100mm dish.  At 72h post 
seeding  the PPARγ agonist, troglitazone (Trog), or DMSO vehicle (Control) was used 
to treat the cells.  After 48h of troglitazone treatment, cellular growth was determined by 
crystal violet staining as described in materials and methods.  Results are expressed as 
fraction of control.  Experiments were performed in triplicate and figure is representative 
of 3 or more independent assays.  Error bars represent standard error.
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 Figure 8:  Anchorage-dependent growth study in SK-Mel 28 treated with 
troglitazone 
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Figure 9:  Anchorage-dependent growth study in A375 treated with PGJ2.  A375 
cells were seeded at 5.0x105 cells per 100mm dish.  At 72h post seeding, the PPARγ 
agonist, PGJ2, or DMSO vehicle (Control) was used to treat the cells.  After 48h of 
PGJ2 treatment, cellular growth was determined by crystal violet staining as described in 
materials and methods. Results are expressed as fraction of control.  Experiments were 
performed in triplicate and figure is representative of 3 or more independent assays.  
Error bars represent standard error.  * denotes p < 0.006 
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Figure 9:  Anchorage-dependent growth study in A375 treated with PGJ2 
 71 
Figure 10:  Anchorage-dependent growth study in A375 treated with ciglitazone.  
A375 cells were seeded at 5.0x105 cells per 100mm dish.  At 72h post seeding the 
PPARγ agonist, ciglitazone (Cig), or DMSO vehicle (Control) was used to treat the 
cells.  After 48h of ciglitazone treatment, cellular growth was determined by 
hemacytometric analysis.  Cells were counted and corrected for DMSO treated (control) 
cell number.  Results are expressed as fraction of control.  Experiments were performed 
in triplicate and figure is representative of 3 or more independent assays.  Error bars 
represent standard error.
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Figure 10:  Anchorage-dependent growth study in A375 treated with ciglitazone  
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Figure 11:  Anchorage-dependent growth study in A375 treated with WY-14643.  
A375 cells were seeded at 5.0x105 cells per 100mm dish.  At 72h post seeding the 
PPARα agonist, WY-14643 (WY), or DMSO vehicle (Control) was used to treat the 
cells.  After 48h of WY-14643 treatment, cellular growth was determined by 
hemacytometric analysis.  Cells were counted and corrected for DMSO treated control 
cell number.  Results are expressed as fraction of control.  Experiments were performed 
in triplicate and figure is representative of 3 or more independent assays.  Error bars 
represent standard error.
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Figure 11:  Anchorage-dependent growth study in A375 treated with WY-14643 
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Figure 12:  Anchorage-dependent growth study in A375 treated with LTB4.  A375 
cells were seeded at 5.0x105 cells per 100mm dish.  At 72h post seeding the PPARα 
agonist, LTB4, or ethanol vehicle (Control) was used to treat the cells.  After 48h of 
LTB4 treatment, cellular growth was determined by hemacytometric analysis.  Cells 
were counted and corrected for DMSO treated control cell number.  Results are 
expressed as fraction of control.  Experiments were performed in triplicate and figure is 
representative of 3 or more independent assays.  Error bars represent standard error.
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Figure 12:  Anchorage-dependent growth study in A375 treated with LTB4. 
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Figure 13:  Anchorage-dependent growth study in A375 treated with troglitazone.  
A375 cells were seeded at 5.0x105 cells per 100mm dish.  At 72h post seeding the 
PPARγ agonist, troglitazone (Trog), or DMSO vehicle (Control) was used to treat the 
cells.  After 48h of troglitazone treatment, cellular growth was determined by crystal 
violet staining as described in materials and methods.  Results are expressed as 
fraction of control.  Experiments were performed in triplicate and figure is representative 
of 3 or more independent assays.  Error bars represent standard error.  * denotes p < 
0.003
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Figure 13:  Anchorage-dependent growth study in A375 treated with troglitazone 
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Figure 14:  Anchorage-dependent growth study in HEMn-LP treated with 
troglitazone.  HEMn-LP cells were seeded at 5.0x105 cells per 100mm dish.  At 72h 
post seeding the PPARγ agonist, troglitazone (Trog), or DMSO vehicle (Control) was 
used to treat the cells.  After 48h of troglitazone treatment, cellular growth was 
determined by crystal violet staining as described in materials and methods.  Results 
are expressed as fraction of control.  Experiments were performed in triplicate and 
figure is representative of 3 or more independent assays.  Error bars represent standard 
error.  * denotes p < 0.002
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Figure 14:  Anchorage-dependent growth study in HEMn-LP treated with 
troglitazone 
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Figure 15:  Melanin production in HEMn-LP treated with troglitazone.  HEMn-LP 
cells were seeded at 5.0x105 into 100mm dishes.  At 72h post-seeding cells were 
treated with troglitazone (Trog) or DMSO vehicle (Control) for 48h.  Subsequently, cells 
were lysed and melanin assay was performed as described in materials and methods.  
Results are corrected for cell number and shown as fraction of control.  Experiments 
were performed in triplicate and figure is representative of 3 or more independent 
assays.  Error bars represent standard error.
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Figure 15:  Melanin production in HEMn-LP treated with troglitazone 
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Figure 16:  Anchorage-dependent growth study in HEMn-LP treated with PGJ2.  
HEMn-LP cells were seeded at 5.0x105 cells per 100mm dish.  At 72h post-seeding, the 
PPARγ agonist, PGJ2, was used to treat the cells.  After 48h of PGJ2 or vehicle (DMSO) 
treatment, cellular growth was determined by crystal violet staining as described in 
materials and methods.   Results are expressed as fraction of DMSO treated (control) 
cells.  Experiments were performed in triplicate and figure is representative of 3 or more 
independent assays.  Error bars represent standard error.
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Figure 16:  Anchorage-dependent growth study in HEMn-LP treated with PGJ2 
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Figure 17:  RT-PCR for PPARs in human melanoma cells. Total RNA was extracted 
from SK-Mel 28 vertical growth phase cells and A375 metastatic melanoma cells at 72 
hours post-seeding when cells were at ~70% confluence.  RNA integrity was 
determined using the Agilent Bioanalyzer®.  RNA was reverse transcribed using the 
Advantage RT-for PCR kit®.  5uL of the resulting cDNA was used in the PCR reaction 
as described in the Advantage cDNA kit® manual using primers specific for either 
PPARγ1, PPARγ2, or PPARδ.
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Figure 17:  RT-PCR for PPARs in human melanoma cells
28 
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Figure 18:  Quantigene® analysis to determine relative expression of PPARα 
mRNA.  The Quantigene® assay system was used to determine the relative levels of 
PPARα mRNA in HEMn-LP, SK-Mel 28, and A375 human melanoma cells.  This assay 
allows quantitation of mRNA species directly from cell lysates without the need to 
isolate total RNA.  Cells were harvested at ~70% confluence.  Total cell extract from 
20,000 cells was loaded in each well of a Quantigene® Capture Plate and hybridized to 
probes specific for PPARα mRNA.  The data is expressed as the fold increase of 
PPARα expression corrected for β-actin expression (internal control) relative to the 
amount of HEMn-LP PPARα expression (also corrected for β-actin expression).
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Figure 18:  Quantigene® analysis to determine relative expression of PPARα 
mRNA 
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Expression of PPAR subtype protein 
 While PPAR subtype mRNA was shown to be present in each cell line tested, the 
protein levels had yet to be determined.  Relative protein expression levels of PPARα 
(Figure 19) and PPARγ (Figure 20) subtypes were determined by western blot 
analysis.  Either whole cell lysates or nuclear extracts from normal human melanocytes, 
SK-Mel 28, or A375 cells were subjected to SDS-PAGE and the resulting blots were 
visualized and density of the immunoreactive PPAR protein signals analyzed using the 
BioRad Chemi-Doc®.  All blots were re-probed with GAPDH antibody and the density of 
the PPAR reactive protein signal divided by the density of the GAPDH signal.  I found 
that PPARα protein levels were highest in the A375 cells (Figure 19).  PPARγ protein 
was ~50% higher in both SK-Mel 28 and A375 melanoma cells relative to the normal 
human melanocytes (Figure 20).   SK-Mel 28 PPARα protein was ~20% less than that 
of A375 cells while the normal human melanocytes had ~70% less than the A375 cells 
(Figure 19). 
Decrease in SK-Mel 28 cell PPARα by siRNA knockdown 
 Since the mRNA levels of PPARα were highest in the SK-Mel 28 cells, siRNA 
targeting PPARα was used to determine the effects of PPARα knockdown on the 
physiology of these human melanoma cells.  Even though consistent 80% PPARα 
mRNA knockdown was achieved (Figure 21), as determined by the Quantigene® 
assay, no major biological effect was seen in these cells.  There was no change in 
morphology in these cells treated with PPARα siRNA compared to control siRNA-
treated cells (Figure 23 A and B).  The expression of MCAD is a direct indicator of 
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PPARα transcriptional activity.  The expression of MCAD should decrease when the 
PPARα level/activity decreases.  This was not the case as shown in Figure 22.
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Figures 19:  PPARα protein expression in human melanoma and normal 
melanocytes.  Fifty µg nuclear extract from SK-Mel 28, A375, and HEMn-LP was 
separated by SDS-PAGE.  The resulting blot was probed with PPARα antibody 
(Panomics, Inc.) at a titer of 1:250 and bands were visualized by chemiluminescence.  
Densitometry was performed and the ratio of PPARα to GAPDH relative to SK-Mel 28 
was calculated.  Data is shown as fraction of control (SK-Mel 28).  M = molecular weight 
marker.
 92 
Figure 19:  PPARα protein expression in human melanoma and normal 
melanocyte 
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Figure 20:  PPARγ protein expression in human melanoma and HEMn-LP.   Fifty µg 
whole cell lysate was extracted from SK-Mel 28, A375, and HEMn-LP and subsequently 
separated by SDS-PAGE.  The resulting blot was probed using Anti-PPARγ (Cell 
Signaling, Inc.) at 1:1000.  Bands were visualized using chemiluminescence detection.  
Densitometric analysis was performed and the ratio of PPARγ to GAPDH relative to SK-
Mel 28 was calculated.  Data is presented as fraction of control (SK-Mel 28).  Data is 
presented fold change. 
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Figure 20:  PPARγ protein expression in human melanoma and HEMn-LP 
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Figure 21:  Quantigene® analysis to determine siRNA knockdown of PPARα.  SK-
Mel 28 cells were seeded at 1.5x105 cells/well into a 6-well plate. At 24 hours post-
seeding, cells were treated with 100nM PPARα siRNA using the RNAifect® kit (Qiagen, 
Inc). Total cellular RNA was isolated 48h or 96h later, using Tri Reagent® (Molecular 
Research Corp. Cincinnati, OH).  RNA integrity was determined using the Agilent 
Bioanalyzer®.  The Quantigene® assay system was used to determine % knockdown of 
the PPARα mRNA.  The Quantigene® assay is based on branched DNA technology 
that allows quantitation of mRNA species from total RNA.  The desired mRNA is 
hybridized to a gene specific probe set, here, PPARα.  The probe set consists of three 
types of probes: Capture Extender, Label Extender, and the Blocking probe, all 
designed to hybridize to the target mRNA.   Total RNA (2 µg/10µL) was loaded in each 
well of a Quantigene® Capture Plate and hybridized to probes specific for PPARα 
mRNA.  The ratio of PPARα to β-actin (internal control) was calculated.  The data is 
presented as a fraction of control siRNA-derived PPARα mRNA levels.
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Figure 21:  Quantigene® analysis to determine siRNA knockdown of PPARα 
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Figure 22:  MCAD protein expression in SK-Mel 28 cells.  Fifty µg whole cell lysate 
was extracted from control and PPARα siRNA treated SK-Mel 28 cells at ~70% 
confluence and subsequently separated by SDS-PAGE.  The resulting blot was probed 
using anti-MCAD (Cayman Chemical, Ann Arbor, MI) at 1:2000.  Bands were visualized 
using chemiluminescence detection.  Equal loading was determined by Ponceau 
staining.  
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Figure 22:  MCAD protein expression in SK-Mel 28 cells 
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Figure 23 A and B:  Images of SK-Mel 28 cells treated with control siRNA (A) or 
PPARα siRNA (B).  Ninety-six hour control siRNA (A) or PPARα siRNA(B) treatment.  
Cell morphology was analyzed by visual analysis using images acquired by Olympus® 
DX-184 microscope.  Images are also representative of 48h siRNA experiment. 
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Figure 23 A and B: Images of SK-Mel 28 cells treated with control siRNA (A) or 
PPARα siRNA (B) 
A 
B 
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DISCUSSION – Part I 
 PPARs have been implicated in a diverse range of biological processes.  They 
have been shown to activate many target genes that regulate a myriad of cellular 
functions including cell cycle progression, differentiation, and apoptosis - all of which are 
important to tumorigenesis.  The first part of my dissertation tests the hypothesis that 
the PPARs play a role in the development and/or progression of human melanoma. 
Initially, I treated either normal human melanocytes, SK-Mel 28, or A375, vertical 
growth phase and metastatic human melanoma cells respectively, with various PPARα 
or PPARγ agonists to determine whether or not these could affect cellular growth, and 
melanin production (Figures 4-16).  I found that no PPARα agonist had any significant 
effect on these human melanocytes and melanoma cells.  Other studies have reported 
similar results in human melanoma, concluding that the PPARα agonist WY-14643 had 
no effect on the growth of A375 human metastatic melanoma cells (Nunez NP, Liu H 
2005).  My western blotting experiments show that PPARα is expressed in these cells.  
However, it has been reported that PPARα may need to be phosphorylated to be fully 
active in some cell lines (Juge – Aubry et al.,1999;  Lazennec et al., 2000).  It could be 
that one of the kinases responsible for this phosphorylation is not fully active, or is not 
present at sufficient levels in these cells.  Another possibility is that a phosphatase is 
overly targeting the activated PPARα resulting in a dephosphorylation, and thus 
deactivation of this receptor in some sort of negative feedback scenario.  Also, it is 
possible that there are sufficient levels of active PPARα but it is saturated with an 
endogenous ligand.  Since the PPARα agonist also did not inhibit the growth of the 
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normal human melanocytes, it is likely that PPARα activation does not lead to inhibition 
of growth in melanocytes/melanoma cells. 
 Unlike PPARα, some PPARγ agonists were shown to have a significant effect on 
cellular growth in the metastatic melanoma cells and the normal human melanocytes.  
Expression and effect of ligand activation of PPARγ has been studied in human 
melanoma.  Both WM35, an early stage melanoma, and A375, a metastatic melanoma 
cell line, have been reported to express PPARγ mRNA and protein.  While one study 
concluded that the growth of A375 cells was inhibited by ciglitazone (Placha et al., 
2003), another showed that the proliferation of A375 cells was unaffected by this 
compound (Nunez et al., 2006).  Ciglitazone had no effect on either SK-Mel 28 or A375 
in these studies (Figures 6 and 10 respectively).  PGJ2, a natural PPARγ agonist, 
significantly inhibited A375 metastatic melanoma cell growth ~30% at 10µM compared 
to DMSO treated cells (Figure 9).  PGJ2 had no reproducible significant impact on 
anchorage dependent growth or melanin production in the SK-Mel 28 vertical growth 
phase (Figures 4 and 5 respectively) cells.  PGJ2 had no reproducible significant effect 
on the anchorage dependent growth in normal human melanocytes either (Figure 16).  
Troglitazone, a potent synthetic PPARγ agonist, had a significant impact on cellular 
growth in both the A375 cells (Figure 13) and the normal human melanocytes (Figure 
14).  At 10µM, TZD inhibited A375 cellular growth by ~55% compared to DMSO treated 
cells.  Normal human melanocytes showed a clear dose dependent response to TZD 
with the 10µM treatment significantly inhibiting cellular growth by ~40% compared to 
DMSO controls.   
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Troglitazone had no reproducible significant impact on the SK-Mel 28 vertical 
growth phase cells.  Expression and effect of ligand activation of PPARγ has been 
studied in human melanoma by others as well.  While one study concluded that the 
growth of A375 cells was inhibited by ciglitazone (Placha et al., 2003), another showed 
that the proliferation of A375 cells was unaffected by this PPARγ agonist (Nunez et al., 
2006).  It has been reported by others that PPARγ protein is expressed in WM35, an 
early stage melanoma, and A375, the metastatic melanoma cell line (Placha et al., 
2003).  My western blot analysis (Figure 20) shows that PPARγ is overexpressed in the 
SK-Mel 28 cells relative to the normal human melanocytes, however it seems to not be 
active in these cells.  Neither PGJ2, TZD, nor ciglitazone had any significant affect on 
these vertical growth phase cells.  In contrast to PPARα, PPARγ phosphorylation results 
in an inhibition of transcriptional activation of this receptor (Camp et al., 1999;  Adams et 
al., 1997).  It is possible that there is a mutation in the PPARγ amino acid sequence at 
either of the serines that are candidates for phosphorylation (Ser 82, 84, 110, or 112) 
which results in a constitutively-inactive pseudophosphorylated conformation in these 
cells.  Another possible explanation is that the kinases responsible for the 
phosphorylation of PPARγ are overexpressed or overly active in these cells resulting in 
a hyperphosphorylated (thus inactive) PPARγ protein.  Conversely, a phosphatase that 
could be responsible for removing the phosphorylation from PPARγ could be inactivated 
in these cells.   Any of these changes, together with increased expression relative to 
normal human melanocytes would result in a dominant-negative PPARγ in SK-mel 28 
cells. 
 Next, I determined whether the human melanoma cells expressed the various 
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PPAR subtype mRNAs.  PPARδ and PPARγ1 and PPARγ2 are expressed in both SK-
Mel 28 and A375 cells according to RT-PCR results (Figure 17).  PPARα mRNA was 
measured quantitatively using the Quantigene® assay system.  Quantigene analysis of 
the relative amounts of these PPAR subtypes was not performed, since no PPARγ 
probes were available at the time of these experiments.  PPARα mRNA was ~2 fold 
higher in the SK-Mel 28 cells relative to both the normal human melanocytes and the 
A375 metastatic cells (Figure 18).  The PPARα mRNA level in the A375 was only a 
negligible 0.14 fold higher than in the normal human melanocytes.  This was not 
consistent with the protein levels of PPARα, in these cells (discussed below).  I 
determined whether the various subtypes of PPARs are expressed at the protein level 
in these cell lines.  After numerous attempts, I found that both PPARα and PPARγ are 
expressed in normal human melanocytes, vertical growth phase melanoma SK-Mel 28 
cells, and metastatic melanoma A375 cells (Figures 19 and 20).  PPARα protein was 
highest in the A375 cells, being ~30% higher in these cells than in the SK-Mel 28 cells.  
Normal human melanocytes, HEMn-LP, expressed the least amount of PPARα at ~60% 
less than SK-Mel 28 and ~80% less than the A375 cells.  This does not correlate with 
the mRNA data from the same cell lines, where SK-Mel 28 cells had the highest levels 
of PPARα mRNA, while A375 and HEMn-LP cells were nearly equal.  This 
inconsistency could be attributed to the fact that PPARα can be degraded via the 
ubiquitin-proteasome pathway (Blanquart et al., 2002).  It is possible that even though 
the mRNA levels of PPARα are highest in the SK-Mel 28 cells, the PPARα protein in 
these cells could be ubiquitinated at a higher rate relative to the A375 metastatic cells.  
This would result in lower overall PPARα protein levels in the SK-Mel 28 cells compared 
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to the A375 cells.  PPARγ protein levels were consistently ~50% higher in the human 
melanoma cells, SK-Mel 28 and A375, relative to the normal human melanocytes. 
 Lastly, I explored PPARα loss of function in the SK-Mel 28 vertical growth phase 
cells.  Since the mRNA levels of PPARα were highest in the SK-Mel 28 cells, I decided 
to silence the expression of this gene using siRNA to determine how loss of PPARα 
expression in these cells might affect their function.  siRNA treatment from 48h up to 
96h showed consistent knockdown of PPARα mRNA by ~80% in the SK-Mel 28 vertical 
growth phase cells (Figure 21).  Even though the knockdown was significant and 
persistent, there was no observable biological effect in terms of morphology (Figures 
23 A and B), nor was there any decrease in the expression of a PPARα target gene 
MCAD (medium chain acyl-CoA dehydrogenase) (Figure 22).  This lack of biological 
effects could be due to the fact that there is redundancy of PPAR function between the 
subtypes.  In cells where PPARα is decreased the other PPARs, namely PPARγ, could 
compensate for this loss.  Another explanation is that 80% knockdown is not enough to 
completely abolish PPARα function in these cells.  However, the 80% knockdown of 
PPARα results in an RNA level considerably below that found in normal human 
melanocytes and therefore a reasonable conclusion is that the increased expression of 
PPARα in SK-Mel28 melanoma cells is not contributing to its in vitro transformed 
phenotypes.
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INTRODUCTION TO DISSERTATION PART II 
The incidence of melanoma is increasing more rapidly than any other tumor type.  
Melanoma accounts for 4% of all skin cancers, but for 79% of all skin cancer-related 
deaths in the United States (Melanoma Research Foundation).  It is notoriously 
resistant to both chemo- and radiotherapy (Soengas and Lowe 2003).  Melanoma cells 
derive from the skin’s natural defense system to UV light, the melanocyte.  Melanocytes 
absorb UV light and in response, produce the pigment, melanin.  To defeat the stresses 
of this unique function, the melanocytes are inherently and naturally resistant to 
apoptosis (Soengas and Lowe 2003).  Understanding the molecular changes involved in 
the progression of melanoma as well as the basis of its resistance to current therapies 
is imperative to devising new strategies for its treatment. 
One of the potential regulators of melanoma progression is the heterodimeric 
transcriptional complex, HIF-1, also known as the master regulator of O2 homeostasis in 
cells (Semenza G., 2003).  HIF-1 controls over 60 genes involved in many aspects of 
oncogenesis, including tumorigenesis (Kondo et al., 2005; Zhang et al., 2004).  Several 
markers of tumorigenesis have been shown to be altered by either the overexpression 
or inhibition of HIF-1.  Hypoxia-induced or exogenous overexpression of HIF-1α directly 
increased in vitro invasion by the human colon adenocarcinoma cells, HCT116 
(Krishnamachary et al., 2003).  Pancreatic cancer cells, PCI-10, which were 
overexpressing exogenous HIF-1α showed a significant increase in the frequency of 
xenograft growth post injection (Akakura et al., 2001).  Inhibition of HIF-1α activity by 
 107 
overexpression of a dominant-negative form of HIF-1α in pancreatic cancer cells, PCI-
43, resulted in an increase in apoptotic cells and a decrease in their ability to form 
tumors in SCID mice (Chen et al., 2003).  Other genes controlled by HIF-1 include those 
involved in apoptosis (Zhang et al., 2004; Greijer, A. 2004) and genetic instability 
(Koshiji et al., 2005).  HIF-1 has also been implicated in the progression of several 
cancers including mammary gland, prostate, brain, and lung (Goda et al., 2003).  HIF-
1α is the regulatory subunit of HIF-1.  It is regulated at the protein level by both oxygen- 
dependent and independent pathways (Semenza G., 2002).  Overexpression of HIF-1α 
has been shown to increase the tumorigenic potency of renal cell carcinoma and 
bladder cancer cells (Kondo et al., 2005).  HIF-1α inhibition by siRNA in HCT116 
(human colon cancer) cells resulted in no tumor growth compared to control cells when 
introduced into nude mice (Zhang et al., 2004). 
HIF-1α785 is a novel splice variant of HIF-1α that is characterized by excision of 
exon 11 and splicing of exons 10 and 12 (Chun et al., 2003).  While this splice variant 
retains the remainder of the functional domains of HIF-1α, it loses lysine 532 in exon 11 
that is usually acetylated by the acetyltransferase, ADP-ribosylation factor domain 
protein 1 (ARD-1) (Jeong et al., 2002).  This acetylation on lys 532 of HIF-1α is critical 
for enhanced HIF-1α binding to the von Hippel Lindau (VHL) tumor suppressor protein, 
which acts as an E3 ubiquitin ligase.  VHL binding to HIF-1α brings about degradation 
of HIF-1α by the proteasome.  Since binding to VHL is a critical component of HIF-1α 
degradation, HIF-1α785 is rendered more stable by lacking this lysine 532. 
In addition to the stability, there are other characteristics that set the splice 
 108 
variant apart from full length HIF-1α.  HIF-1α785 has been shown to be regulated by 
different stimuli and pathways in comparison to HIF-1α.  HIF-1α785 does not require 
hypoxic conditions to be stabilized.  Instead, HIF-1α785 can be stabilized by the phorbol 
ester, PMA (Lim et al., 2004).   HIF-1α785 has also been shown to be upregulated in 
response to hyperthermia (42ºC) as well as by the Ras/Raf/MEK/ERK pathway (Lim et 
al., 2004).  In an in vivo nude mouse model, this splice variant was shown to render a 
faster growing, larger, and more hypervascular tumor than HIF-1α (Chun et al., 2003).  
Expression and role of HIF-1α785 in melanoma has yet to be elucidated. 
The hypothesis was that inhibition of HIF-1α or HIF-1α785 would decrease 
tumorgenicity in the human metastatic melanoma cells while overexpression of HIF-1α 
or HIF-1α785 in radial growth phase cells would increase their tumorgenicity.  In this 
part of my thesis I found that this splice variant is expressed in human melanoma cell 
lines while it is significantly lower in the normal human melanocytes.  qPCR data shows 
an increase in HIF-1α and especially HIF-1α785 mRNA as a function of malignant 
progression, while remaining nearly undetectable in normal human melanocytes.  
Overexpression of HIF-1α and HIF-1α785 resulted in increased anchorage independent 
growth in the radial growth phase SbCl2 human melanoma cells, with HIF-1α785 having 
a greater effect.  Knockdown of HIF-1α by siRNA in the human metastatic melanoma 
cell line, WM9, resulted in a ~50% decrease in matrigel invasion.  Suppression of HIF-
1α also led to a ~50% - 60% decrease in anchorage independent growth in the WM9 
cells.  The gain of function data in SbCl2 radial growth phase human melanoma cells 
indicates that the putative tumor promoter, HIF-1α785, is a potent effector of 
tumorgenicity in these cells.  These data show that the full length HIF-1α is able to 
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increase soft agar colony formation, while the HIF-1α785 variant has an even greater 
effect.  The loss-of-function data for HIF-1α induced by siRNA, suggest that inhibition of 
this transcription factor in metastatic human melanoma cells has a negative effect on 
tumorgenicity. 
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CHAPTER II 
Function of HIF-1 in human melanoma progression 
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MATERIALS AND METHODS 
Cell lines and cell culture conditions 
 SbCl2 (RGP), WM1366 (VGP), and WM9 (Metastatic melanoma) cells were a 
generous gift from Meenhard Herlyn’s lab at the Wistar Institute (University of 
Pennsylvania).  All cells were incubated in a humidified incubator with 5% CO2 and 95% 
air at 37°C.  The SbCl2 cells were cultured in MCDB153 media (Invitrogen, Carlsbad 
CA), a powder brought up in autoclaved ddH20. Sodium bicarbonate (1.2g/L) was added 
and the pH was adjusted to ~7.4 using NaOH.  Approximately 400mL of the resulting 
liquid MCDB153 media was supplemented with 10 mL fetal bovine serum, 800uL CaCl2, 
250uL insulin (Sigma Chemical, St. Louis, MO), and 5mL penicillin/streptomycin solution 
at 10,000 U/L (Invitrogen Corp., Carlsbad CA).  WM1366 and WM9 cells were cultured 
in RPMI medium (Invitrogen Corp., Carlsbad CA).   RPMI (500 mL) was supplemented 
with 10% fetal bovine serum and 5 mL penicillin streptomycin solution.  Normal human 
melanocyte (HEMn-LP) cell culture conditions were as described previously. 
Western Blot analysis of HIF-1α 
Nuclear extracts from each cell line were isolated using the NePER kit® (Pierce, 
Rockford, IL) according to the manufacturer’s protocol when cells were no more than 
~70% confluent.  Protein concentration was determined using the BCA protein assay 
reagents from Pierce as per the manufacturer’s instructions.  Proteins were separated 
by SDS-PAGE and transferred to nitrocellulose membranes using the BioRAD 
MiniProtean3® system.  Equal loading was also determined by Ponceau staining of the 
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nitrocellulose membranes.  Blots were blocked using ChemiBlocker® reagent 
(Chemicon, Temecula, CA) and probed overnight at 4°C with anti-HIF-1α monoclonal 
antibody at 1ug/mL (R&D Systems, Minneapolis, MN).  Monoclonal mouse secondary 
IgG antibody (GE Healthcare, Piscataway, NJ) was applied after three 100 mL 1x TBS + 
0.05% Tween (TBS-T) washes.  Blots were incubated with secondary antibody at 
1:3,000 for 1h at room temperature and subsequently washed 3x with100mL  1x TBS-T.  
A final 5 minute wash with 100mL TBS (no Tween) was performed just prior to 
incubating the blot with ECL reagent (GE Healthcare, Piscataway, NJ).  Blots were then 
autoradiographed. 
RT-PCR for HIF-1α and HIF-1α785 
RT-PCR was carried out as described previously.  Primers were designed to 
either amplify only HIF-1α or HIF-1α785 exclusively.  HIF-1α primers would exclude 
HIF-1α785 by targeting exon 11, which is absent in HIF-1α785.  HIF-1α785 primers 
were designed to exclude HIF-1α by targeting the exon 10:12 boundary only present in 
HIF-1α785.  The sequence of HIF-1α forward primer is 5’-
AAAGTTCACCTGAGCCTAAT-3’, and the sequence of the reverse primer is 5’-
TAAGAAAAAGCTCAGTTAAC-3’.  The sequence of HIF-1α785 forward primers is 5’-
AAAGTTCACCTGAGGACAC-3’.  The sequence of the HIF-1α785 reverse primer is 5’-
TAAGAAAAAGCTCAGTTAAC-3’. 
Quantitative PCR for HIF-1α and HIF-1α785 
 Total RNA was extracted from HEMn-LP, SbCl2, WM1366, and WM9 cells at 
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both 24h (~40% confluent) and 72h (~70% confluent) after seeding using TRIZOL® 
reagent according to the manufacturer’s protocol.  RNA was then converted to cDNA 
using the High Capacity cDNA Archive Kit (Applied Biosystems Inc. (ABI), Foster City, 
CA).  qPCR analysis was performed using TaqMan probes for HIF-1α (ABI Catalog 
number Hs00936366) or HIF-1α785 (ABI Custom Primer Order) as well as β-actin (ABI 
Catalog number 4326315E).  The reactions were performed under conditions specified 
in the ABI TaqMan Gene Quantitation assay protocol.  Data was corrected for efficiency 
and loading using the Pfaffl method (Pfaffl M., 2001).  Data are representative of at least 
3 separate experiments. 
Overexpression of HIF-1α or HIF-1α785 in SbCl2 cells 
 The pLenti-V5-D-TOPO vector was used in gain of function experiments in the 
SbCl2 radial growth phase human melanoma cells.  I cloned either HIF-1α or HIF-1α785 
into this vector by amplifying these genes by primers specific for both the 5’ and 3’ ends 
of HIF-1α.  The linearized pLenti-V5-D-TOPO Vector contains a GTGG overhang at one 
end while the insert is Taq Amplified to contain a 5’-CACC overhang at one end.  
Following amplification, 20µL of the 50µL PCR amplification reactions were separated 
on a 1% agarose gel stained with ethidium bromide to ensure the correct size amplicon 
was present.  HIF-1α and HIF-1α785 amplicons were purified from the remainder of the 
PCR reaction using the Zymo DNA Clean & Concentrate Kit® (Zymo Research Inc., 
Orange, CA).  After ligation, plasmids were transformed into a premade OneShot® vial 
of Stbl3® competent cells (Invitrogen Corp., Carlesbad, CA) and plated onto agar plates 
containing 100ug/mL ampicillin.  Plates were incubated at 37°C overnight and then 
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colonies were screened for intact insert in the correct orientation.  Plasmids were 
isolated from positive colonies and analyzed by DNA sequencing to ensure the correct 
plasmid expression construct.  Control plasmid, pLenti-V5-LacZ, was supplied in the 
ViraPower kit® (Invitrogen Corp., Carlsbad, CA). 
siRNA inhibition of HIF-1α in WM9 human metastatic cells 
 WM9 cells seeded into 6 well plates at 5.0 x 104 cells per well were treated 24h 
after seeding with either 100nM HIF-1α siRNA or 100nM control non-targeting siRNA 
(Dharmacon, Inc. Lafayette, CO) using the RNAifect® transfection reagent (Qiagen, 
Inc.) as per the manufacturer’s instructions.  Briefly, siRNA oligos were diluted to a 
stock concentration of 10mM using 1x siRNA buffer (Dharmacon, Inc. Lafayette, CO).  
Final concentration of siRNA (100 nM) was obtained by diluting stock into the 
appropriate amount of RNAifect® transfection reagent as per product manual.  HIF-1α 
down-regulation was confirmed by western blot at 48, 72, 96, and 120h after 
transfection.  There was ~60% - 70% decrease in HIF-1α protein relative to control 
siRNA treated WM9 cells at each time point. 
Matrigel invasion assay 
 WM9 cells treated with either 100nM HIF-1α siRNA or 100nM control non-
targeting siRNA (Dharmacon, Inc.) for 24h were seeded into 6-well matrigel (+) 
chambers, and, as a control, 6-well matrigel (-) chambers (BD Biosciences) at 7.0x104 
cells per well.  At 24 hours post-seeding, the matrigel was removed from the chambers 
using a cotton-tipped applicator.  After all the matrigel on the inner part of the chambers 
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was removed, invading cells were fixed with 80% methanol for 5 minutes and then 
stained with 0.5% crystal violet for 5 minutes.  After staining, the cells/chambers were 
extensively washed in dH2O.  Once excess stain was removed, cells were manually 
counted using a grid system covering the entire lower surface of the chamber.  Results 
are expressed as % HIF-1α siRNA treated-WM9 invasion relative to control siRNA 
treated-WM9 invasion, both corrected for the invasion of similarly treated cells seeded 
in matrigel (-) chambers. 
Anchorage-independent growth assay 
 CytoSelect 96 well Cell Transformation Assay® (Cell Biolabs, Inc.) was used to 
determine anchorage-independent growth of SbCl2 cells overexpressing either HIF-1α, 
HIF-1α785, or LacZ.  SbCl2 cells were transfected at ~80% confluence with either 
pLenti-LacZ, pLenti-V5-D-TOPO-HIF-1α, or pLenti-V5-D-TOPO-HIF-1α785 using 
FuGene 6 transfection reagent as per manufacturer’s protocol (Roche, Palo Alto, CA).  
The next day 1.0x104 cells from each of the control (non-transfected), LacZ, HIF-1αFL, 
or HIF-1α785 cells were seeded into a 0.4% agar layer poured over a 0.6% agar layer in 
wells of a 96 well plate.  Wells lacking cells served as a fluorescent blank control.  Agar 
layers were solubilized using a multichannel pipette, cells were lysed, and nucleic acid 
content stained with 15µL CyQuant dye.  The amount of Cyquant dye in each well was 
determined using a fluorescent plate detector at 485/520 nm. 
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RESULTS 
Expression of HIF-1α in human melanoma cells 
Here, we show for the first time in human melanoma, the oxygen-labile HIF-1α 
protein is expressed endogenously with no external stimuli under normoxic conditions in 
both metastatic cell lines A375 and WM9.  Normoxic expression of HIF-1α is usually 
inhibited due to the activity of the PHD and ARD1 proteins.  These proteins target the 
HIF-1α subunit for degradation via the ubiquitin-proteasome pathway.  HIF-1α was 
detected as a band ranging from ~114kD – 120kD in nuclear extracts from the 
metastatic human melanoma cells.    Figures 24 A and B show that HIF-1α is clearly 
overexpressed in the A375 and WM9 cells relative to normal human melanocyte 
(HEMn-LP), radial growth phase (SbCl2), and vertical growth phase cells (WM1366).  
Expression of HIF-1α mRNA 
Regulation of HIF-1α at the RNA level, while very rarely mentioned in the 
literature, could be significant in the progression of human melanoma.  I determined 
HIF-1α and HIF-1α785 mRNA levels initially by RT-PCR (Figure 25) and subsequently 
by qPCR (Figure 26 A and B).  Both Figures 25 and 26 show that in the cell lines 
examined, the relative amounts of HIF-1α and HIF-1α785 mRNA increase as a function 
of malignant progression, while remaining nearly undetectable in normal human 
melanocytes.  Primers were designed so that full length HIF-1α would exclude HIF-
1α785 by targeting exon 11, which is absent in HIF-1α785.  Primers for HIF-1α785 
excluded HIF-1α by targeting the exon 10:12 boundary only present in HIF-1α785.  At 
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24h there is an increase of ~9 fold for the HIF-1α full length mRNA over the HEMn-LP 
levels while the HIF-1α785 mRNA levels rise ~8 fold over the HEMn-LP levels.  At 72h 
post seeding, the HIF-1α full length exhibited ~21 fold increase over the HEMn-LP 
levels.   HIF-1α785 mRNA levels showed ~78 fold increase in expression over the 
HEMn-LP.  
HIF-1α and HIF-1α785 gain of function in radial growth phase SbCl2 cells 
The relative levels of HIF-1α protein are nearly undetectable in the early stage 
radial growth phase SbCl2 cells.  To test the hypothesis that overexpresson of HIF-1α in 
a cell line that initially had very low levels could increase their tumorgenicity I used 
these SbCl2 cells as a model for this overexpression.  I wanted to determine the effects 
that HIF-1α or HIF-1α785 overexpression would have on the malignant properties of 
these cells.  HIF-1α or HIF-1α785 was cloned into the pLenti-V5-D-TOPO vector, 
represented in Figure 27.  While cloning of the HIF-1α gene was very routine, the 
successful cloning of the HIF-1α785 fragment with no rearrangements/mutations was 
extremely difficult.  Cloning into lentiviral vectors proves arduous since the long terminal 
repeat sequences in the vectors are prime targets for e. coli-derived rearrangements.  
After numerous attempts, a positive clone was identified.  To be sure that there were no 
rearrangements or mutations, DNA sequencing was performed in the Marshall 
University DNA core facility and an experiment to determine whether or not the V5 
epitope was cloned in frame was performed.  Figure 28 shows that the HIF-1α785 
variant was successfully cloned in frame and tagged with the V5 epitope.  Figure 29 
shows overexpression of HIF-1α or HIF-1α785 in SbCl2 cells leads to increased 
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anchorage-independent growth, with HIF-1α785 having the greater impact.  These 
results do support the hypothesis that in a cell line initially void of HIF-1α or HIF-1α785 
expression can exhibit increased tumorgenicity when these genes, especially the HIF-
1α785 are introduced.  
HIF-1α loss-of-function in human metastatic melanoma WM9 cells 
I have shown that HIF-1α protein is stabilized under normoxic conditions in both 
human metastatic melanoma cell lines.   HIF-1α could be affording these cells certain 
survival advantages, therefore, the effects of HIF-1α inhibition was determined.  To test 
the hypothesis that lowering the levels of HIF-1α in a cell line could lessen the cells 
tumorgenicity, WM9 cells were treated with siRNA targeting HIF-1α.  The siRNA 
treatment decreased the expression of HIF-1α by ~75-85% consistently.  In the human 
metastatic cell line, WM9, knock down of HIF-1α significantly inhibits both matrigel 
invasion and anchorage-independent growth.  Matrigel invasion was decreased in HIF-
1α-siRNA treated WM9 cells by 53% compared to control siRNA treated WM9 cells 
(Figure 30).  Anchorage-independent growth at day 4 was inhibited by 40% relative to 
control siRNA-treated WM9 cells (Figure 31).  Anchorage-independent growth was 
inhibited by 70% at day 5 compared to control siRNA-treated WM9 cells (Figure 32).  
These results support the suggestion that lowering availability of the HIF-1α in the WM9 
cells decreases their tumorgenicity.
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Figure 24 A and B:  HIF-1α protein expression in A375 and HEMn-LP (A) and 
HEMn-LP, SbCl2, WM1366, and WM9 (B).  A.  Sixty µg of cytoplasmic and nuclear 
extracts from ~70% confluent A375 and normal human melanocytes were separated via 
SDS-PAGE and probed with monoclonal anti-HIF-1α (1ug/mL) at 1:10,000.  Equal 
loading was determined by Ponceau staining. This blot is representative of at least 4 
separate experiments.  B.  Sixty µg of nuclear extracts from HEMn-LP (normal human 
melanocytes), SbCl2 (radial growth phase melanoma), WM1366 (vertical growth phase 
melanoma), and WM9 (metastatic melanoma) were separated via SDS-PAGE and 
probed with monoclonal anti-HIF-1α (1ug/mL) at 1:10,000.  Equal loading was 
determined by Ponceau staining.  This blot is representative of at least 4 separate 
experiments.  M = molecular weight marker.
 120 
Figure 24:  HIF-1α protein expression in A375 and HEMn-LP (A) and HEMn-LP, 
SbCl2, WM1366, and WM9 (B)
A. 
B. 
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Figure 25:  RT-PCR for HIF-1α and HIF-1α785 in HEMn-LP, SbCl2, WM1366, and 
WM9.  Total RNA was extracted from normal human melanocytes (HEMn-LP), radial 
growth phase (SbCl2), vertical growth phase (WM1366), and metastatic melanoma cells 
(WM9).  RNA integrity was determined using the Agilent Bioanalyzer®.  RNA was 
reverse transcribed using the Advantage RT-for PCR kit®.  5uL of the resulting cDNA 
was used in the PCR reaction as described in the Advantage cDNA kit® manual.  
Primers for HIF-1α and HIF-1α785 were designed to specifically amplify each variant 
with no cross-amplification.  Primers for the housekeeping gene control GAPDH were 
included in the Advantage cDNA kit®.  Control primers amplifying a fragment of the 
control plasmid included in the Advantage cDNA kit® were used to ensure optimal PCR 
conditions.  M = molecular weight marker.
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Figure 25:  RT-PCR for HIF-1α and HIF-1α785 in HEMn-LP, SbCl2, WM1366, and 
WM9
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Figure 26 A and B:  qPCR for HIF-1α and HIF-1α785 in HEMn-LP, SbCl2, WM1366, 
and WM9 at 24h (A) or 72h (B).  Total RNA was extracted from HEMn-LP, SbCl2, 
WM1366, and WM9 cells at both 24 (A) and 72h (B).  RNA was then converted to cDNA 
using the High Capacity cDNA Archive Kit (ABI).  qPCR analysis was performed using 
TaqMan probes directed at HIF-1α or HIF-1α785 as well as β -actin.  The reactions 
were performed under conditions specified in the ABI TaqMan Gene Quantitation assay 
protocol.  Data was corrected for efficiency and loading using the Pfaffl method.  Data is 
presented as fold change corrected for β-actin relative to HEMn-LP.   Data is 
representative of at least 3 separate experiments. 
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Figure 26 A and B:  qPCR for HIF-1α and HIF-1α785 in HEMn-LP, SbCl2, WM1366, 
and WM9 at 24h (A) or 72h (B) 
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Figure 27:  Representation of the pLenti-V5-D-TOPO vector.  Representation of the 
pLenti-V5-D-TOPO vector (taken from Invitrogen Corp.) used in gain of function 
experiments in the SbCl2 radial growth phase human melanoma cells.  Both full length 
genes for HIF-1α and HIF-1α785 were amplified by primers specific for HIF-1α.  A 
linearized D-TOPO Vector contains a GTGG overhang at one end while the insert is 
Taq Amplified containing a 5’ -CACC overhang at one end.  Expression results in the 
protein of interest tagged with the V5 epitope.  The V5 epitope tag is derived from a 
small epitope (Pk) present on the P and V proteins of the paramyxovirus of simian virus 
5.  It usually consists of either all 14 amino acids (GKPIPNPLLGLDST) or sometimes a 
shorter version consisting of only 9 amino acids (IPNPLLGLD). 
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Figure 27:  Representation of the pLenti-V5-D-TOPO vector taken from Invitrogen 
Corp.
 127 
Figure 28: Expression of HIF-1α785 tagged with the V5 epitope in SbCl2 cells.  
SbCl2 cells were transiently transfected with pLenti-D-TOPO-HIF-1α785.   At 48h post 
transfection, cells were lysed and whole cell lysate was extracted and separated by 
SDS-PAGE.  After transfer and blocking with Chemi-Blocker®, HRP-conjugated Anti-V5 
antibody was incubated with the membrane for 1h.  After extensive washing and a 5 
minute incubation with ECL® reagent, bands were visualized using autoradiography.  
Molecular weight marker, MagicMark XP® (M), was used to confirm correct kD size for 
the expected expression product (~87kD).
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Figure 28:  Expression of HIF-1α785 tagged with the V5 epitope in SbCl2 cells.
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Figure 29:  Anchorage-independent growth of SbCl2 cells expressing HIF-1α or 
HIF-1α785.  CytoSelect 96 well Cell Transformation Assay® (Cell Biolabs, Inc.):  SbCl2 
cells were transfected at 80% confluence with either pLenti-LacZ, pLenti-V5-D-TOPO-
HIF-1aFL, or pLenti-V5-D-TOPO-HIF-1α785 using FuGene 6 transfection reagent.  The 
next day 1.0x104 of each of the control (non-transfected), LacZ, HIF-1aFL, or HIF-1a-
785 cells were seeded into a 0.4% agar layer poured over a 0.6% agar layer in wells of 
a 96 well plate.  Wells lacking cells served as a blank control.  Agar layers were 
solubilized, cells were lysed, and nucleic acid stained with CyQuant dye.  The intensity 
of fluorescence in the well was determined by a fluorescent plate reader at 485/520 nm.  
Data is shown as relative light units of CyQuant® fluorescence.  Figure is representative 
of at least 3 experiments. 
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Figure 29:  Anchorage-independent growth of SbCl2 cells expressing HIF-
1α or HIF-1α785
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Figure 30:  Matrigel invasion assay in WM9 cells treated with HIF-1α siRNA.  WM9 
cells were treated with either 100nM HIF-1α siRNA or 100nM control #1 non-targeting 
siRNA (Dharmacon, Inc.) using the RNAifect® transfection reagent (Qiagen, Inc.).  At 
24h post transfection, the cells were seeded into 6-well matrigel (+) chambers, and as a 
control, 6-well matrigel (-) chambers (BD Biosciences) at 7.0x104 cells per well.  At 24 
hours after seeding, the matrigel was removed from the matrigel (+) chambers using a 
cotton-tipped applicator.  After all matrigel on the inner part of the chambers was 
removed, invading cells were fixed with 80% methanol for 5 minutes and then stained 
with 0.5% crystal violet for 5 minutes.  After staining, the cells/chambers were 
extensively washed in enough dH2O to remove excess stain.  Once excess stain was 
removed, cells were manually counted using a grid system covering the entire lower 
surface of the chamber.  The number of invaded cells treated with HIF-1α siRNA 
relative to the number of invaded cells treated with control siRNA was determined.  Both 
were corrected for the number of similarly-treated invading cells seeded in matrigel (-) 
chambers.  Results are expressed as cell number as % control.  Experiment was done 
in triplicate and repeated at least 3 times.  Error bars represent standard error. * 
denotes p = 0.0022.
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Figure 30:  Matrigel invasion assay in WM9 cells treated with HIF-1α siRNA 
 133 
Figure 31:  Anchorage independent growth of WM9 cells treated with HIF-1α 
siRNA – Day 4.  WM9 cells were treated with either 100nM HIF-1α siRNA or 100nM 
control #1 non-targeting siRNA (Dharmacon, Inc.) using the RNAifect® transfection 
reagent (Qiagen, Inc.).  At 24h post transfection, anchorage independent growth was 
analyzed using the CytoSelect 96 well Cell Transformation Assay® (Cell Biolabs, Inc.).  
Briefly, the cells were seeded at 8.0x103 cells/well into a 0.4% agar layer poured over a 
0.6% agar layer in wells of 96 well plate.  Wells lacking cells served as a blank control.  
On day 4 after seeding, agar layers were solubilized, cells were lysed, and nucleic acid 
stained with CyQuant® dye.  Intensity of the fluorescence in each well was determined 
by a fluorescent plate reader at 485/520 nm.  Results are expressed in Relative 
Fluorescent Units.  Experiment was done in triplicate and repeated at least 3 times.  
Error bars represent standard error.  * denotes p = 0.032
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Figure 31:  Anchorage independent growth of WM9 cells treated with HIF-1α 
siRNA – Day 4 
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Figure 32:  Anchorage independent growth of WM9 cells treated with HIF-1α 
siRNA – Day 5.  WM9 cells were treated with either 100nM HIF-1α siRNA or 100nM 
control #1 non-targeting siRNA (Dharmacon, Inc.) using the RNAifect® transfection 
reagent (Qiagen, Inc.).  At 24h post transfection, anchorage independent growth was 
analyzed using the CytoSelect 96 well Cell Transformation Assay® (Cell Biolabs, Inc.).  
Briefly, the cells were seeded at 8.0x103 cells/well into a 0.4% agar layer poured over a 
0.6% agar layer in wells of a 96 well plate.  Wells lacking cells served as a blank control.  
On day 5 after seeding, agar layers were solubilized, cells were lysed, and nucleic acid 
stained with CyQuant® dye.  Fluorescence intensity in each well was determined by a 
plate reader at 485/520 nm.  Results are expressed in Relative Flourescent Units.  
Figure is representative of at least 3 independent assays each done in triplicate.  Error 
bars represent standard error.  * denotes p = 0.0016 
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Figure 32:  Anchorage independent growth of WM9 cells treated with HIF-1α 
siRNA – Day 5 
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DISCUSSION – Part II 
For the second half of my dissertation work, I wanted to determine the role of the 
hypoxia inducible factor -1α (HIF-1α) and its splice variant, HIF-1α785 in human 
melanoma progression.   These results indicate that HIF-1α and its variant likely play 
important roles in the progression of this disease. 
Melanocytes, the cells responsible for producing the skin-coloring pigment, 
melanin, are the point of origin for melanoma.  Melanoma, if diagnosed and treated 
early, has a very high cure rate.  If the melanoma progresses, it can metastasize 
(becoming metastatic melanoma) to the lymph nodes, lungs, and the brain.  Metastatic 
melanoma is very difficult to treat and has a much higher mortality rate than primary 
melanoma.  Several studies have confirmed that HIF-1α is very often a survival factor in 
various cancers, however this has not been shown in human melanoma.   
I found that HIF-1α protein is expressed under normoxic conditions at higher 
levels in human metastatic melanoma cells (A375 and WM9) than in the normal human 
melanocytes (HEMn-LP), radial growth phase melanoma (SbCl2), and vertical growth 
phase melanoma (WM1366) cells (Figure 24 A and B) .  The fact that it is detectible in 
the metastatic cells is novel, since it is very quickly degraded under normoxic conditions 
in the majority of all cell lines tested to date. 
More importantly, I have shown that both the full length HIF-1α as well as its 
splice variant, HIF-1α785, show increasing levels of mRNA expression as a function of 
malignant progression (Figure 26 A and B).  Once corrected for both a housekeeping 
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gene and for primer/probe binding efficiency, the metastatic melanoma cells, WM9, 
showed ~10 fold increase in both HIF-1α and HIF-1α785 mRNA levels relative to the 
normal human melanocytes at 24h after seeding and ~21 fold increase over normal 
human melanocytes at 72h after seeding in the HIF-1α.  There was nearly a 78 fold 
increase in the expression of HIF-1α785 in the metastatic melanoma cells over the 
normal human melanocytes at the 72h time point.  These time points are significant 
since in the literature there are hints that “crowding” of the cells in culture dishes can 
influence HIF-1α protein levels.  At 24h after seeding there was around 30% confluence, 
while at 72h there was ~70% confluence.  All protein isolations were done at 48h post-
seeding, therefore it can reasonably be concluded that this “crowding” effect should not 
have been a confounding variable in my western blot data.  While there is some chance 
that these results could be due to the cells being exposed to different culture conditions, 
there is currently no way to correct for this situation.  However, it does seem reasonable 
that if the normal human melanocytes need a certain microenvironment to flourish in 
vivo and the RGPs need an even more altered microenvironment in vivo, and so on for 
the other phases of human melanoma represented here, that these different culture 
conditions in vitro are valid for comparison.   
There is very little information from any cell line on regulation of HIF-1α or its 
variant at the RNA level.  Thus my findings are significant since they indicate a novel 
control point for HIF-1 activity in human melanoma, as well as in other cell lines.  This 
RNA regulation could be due to transcription factors responsible for HIF-1α/HIF-1α785 
gene expression becoming overexpressed or over-active as a function of melanoma 
progression.  However, since I have not shown that the increase in HIF-1α mRNA is due 
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to increased transcription, there remains the formal possibility that post-transcriptional 
regulation, such as increased mRNA stability could contribute to the increase I observed 
in the melanoma cells.  This overexpression of HIF-1α and thus availability of the active 
HIF-1 heterodimer, would give these cells a survival advantage.  One survival 
advantage that HIF-1 overexpression could lend to the metastatic cells is their ability to 
invade and metastasize since HIF-1 is a transcriptional regulator of many genes 
involved in these processes, such as matrix metalloproteinases (MMPs).   
The SbCl2 radial growth phase melanoma cells showed negligible levels of HIF-
1α protein expression and were therefore chosen to determine the effects of HIF-1 gain 
of function.  I have shown that the human melanoma radial growth phase cell line, 
SbCl2, which has very limited anchorage independent growth capabilities, has an 
increased ability to grow in soft agar when overexpressing full length HIF-1α.  
Overexpression of the HIF-1α785 splice variant resulted in the greatest increase in soft 
agar colony formation relative to control cells (Figure 29).  One possibility for the 
increased anchorage independent growth exhibited in the splice variant HIF-1α785-
overexpressing cell line is the splice variant protein having a longer half-life compared to 
the full length HIF-1α.  The longer half life for HIF-1α785 is presumed since it is missing 
a critical Lys532 that is acetylated by ARD1.  This acetylation enhances HIF-1α 
interaction with the von Hipple Lindau tumor suppressor protein which acts as an E3 
ubiquitin ligase.  Without this acetylation, HIF-1α could have a less favorable interaction 
with this protein, therefore increasing the chances it will not be degraded by the 
ubiquitin-proteosomal system.  HIF-1α785 has the same function as HIF-1α; therefore 
longer half life could ultimately lead to more active heterodimeric HIF-1 available for 
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cellular processes.  Future studies need to be done to determine the relative half-life of 
both the full length and splice variant using traditional methods. 
HIF-1α loss of function experiments were carried out in the WM9 metastatic 
melanoma cell line.  This cell line was chosen due to its high levels of HIF-1α 
expression.  Silencing of HIF-1α by siRNA treatment resulted in a significant decrease 
(52%) in matrigel invasion compared to WM9 cells treated with control siRNA (Figure 
30).  One possibility of these results is that HIF-1 has been shown to control the 
expression of several genes involved in invasion such as matrix metalloproteinase 2 
(MMP2), urokinase plasminogen activator receptor (uPAR), and cathepsin D 
(Krishnamachary et. al., 2003; Luo et. al., 2006). 
HIF-1α loss of function also resulted in a significant decrease in anchorage-
independent growth in the metastatic melanoma cells.  Silencing of WM9 cell HIF-1α by 
siRNA resulted in ~40% decrease in their ability to form colonies in soft agar at 4 days 
of treatment (Figure 31).  After 5 days of treatment, there was ~68% decrease in 
anchorage-independent growth in the HIF-1α silenced WM9 cells relative to the control 
siRNA treated cells (Figure 32).  Anchorage-independent growth is a hallmark of cancer 
cells.  The WM9 cells were shown to have a marked increase in the endogenous 
amount of HIF-1α protein according to western blotting (Figure 24 A and B).  
Anchorage-independent growth could be decreased in the WM9 cells treated with HIF-
1α siRNA due to PI3K/Akt and HIF-1 pathway interactions.  The PI3K/Akt pathway is 
one of the most critical pathways involved in anchorage-independent growth (Wang L., 
2004).  Anoikis, or cellular death due to loss of interaction with the extracellular matrix 
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and subsequent initiation of caspase-mediated apoptosis, is increased in these cells 
when HIF-1α levels are depleted by the siRNA treatment.  PI3K/Akt has been shown to 
control HIF-1 activity by increasing the translation of the HIF-1α protein (Treins et. al., 
2002).  If PI3K/Akt regulates anchorage-independent growth through this increased HIF-
1 activity, the silencing of HIF-1α could lead to a decrease in anchorage-independent 
growth.  
The normoxic regulation of HIF-1 has only recently been explored.  Studies are 
needed to determine the role that elevated HIF-1α levels under normoxic conditions 
may play in the progression of cancers.  One future goal of our laboratory is to 
determine whether or not there are different gene sets activated by normoxic HIF-1 
relative to hypoxic HIF-1.  Other future studies could include using the recombinant 
lentiviral particles that I have generated to introduce both full length and the splice 
variant of HIF-1α into normal human melanocytes to determine their effects on 
malignant transformation. 
 
 142 
SUMMARY AND CONCLUSIONS 
The first part of my dissertation work dealt with the expression and possible 
function that PPARs play in human melanocytes compared to human melanoma cells.  
These studies revealed that none of the human melanoma cells tested were 
significantly or reproducibly affected by PPARα agonists, but the normal human 
melanocytes and metastatic melanoma cells, A375 were significantly growth inhibited 
by PPARγ agonists.  While PPARα and PPARγ protein levels are overexpressed 
relative to the normal human melanocytes, only the SK-Mel 28 cells exhibited a 
significant increase in PPARα mRNA levels.  When PPARα expression was silenced in 
SK-Mel 28 cells utilizing siRNA, no observable biological effect was seen in these cells 
compared to cells treated with control siRNA.  A reasonable conclusion is that the 
increased expression of PPARα in SK-Mel 28 cells is not contributing to its in vitro 
transformed phenotype. 
The second part of my dissertation work focuses on the expression and role HIF-
1α, under normoxic conditions in human melanoma progression.  These results 
revealed, for the first time, that HIF-1α is overexpressed in the metastatic melanoma 
cells.  Also, I have shown, for the first time, that there is regulation of HIF-1α at the 
transcriptional level in human melanoma.  The expression of both HIF-1α and HIF-
1α785 increases as a function of melanoma progression.  Gain-of-function studies in the 
HIF-1α-negative SbCl2 cells reveal that introduction of exogenous HIF-1α, or its splice 
variant, can significantly increase their anchorage-independent growth.  Loss-of-function 
studies in the HIF-1α positive WM9 metastatic melanoma cells show that there is a 
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significant decrease in matrigel invasion compared to control siRNA treated cells.  The 
loss of HIF-1α in these cells also significantly diminished their ability to form colonies in 
soft agar.  These results suggest that development of new therapeutic agents that 
inhibit HIF-1 function may be of use in the treatment of human melanoma. 
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